Next Article in Journal
Bioadhesive Surfactant Systems for Methotrexate Skin Delivery
Previous Article in Journal
Discovery of Uracil Derivatives as Potent Inhibitors of Fatty Acid Amide Hydrolase
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 21
Issue 2
10.3390/molecules21020230
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

New 3-Cyano-2-Substituted Pyridines Induce Apoptosis in MCF 7 Breast Cancer Cells

by
Ahmed Malki
1,*,
Mona Mohsen
1,
Hassan Aziz
1,
Ola Rizk
2,3,
Omima Shaban
2,3,
Mohamed El-Sayed
4,
Zaki A. Sherif
5 and
Hayam Ashour
2,*
1
Biomedical Science Program, Department of Health Sciences, College of Art and Sciences, Qatar University, Doha 2713, Qatar
2
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt
3
Department of Analytical and Pharmaceutical Chemistry, Faculty of Pharmacy & Drug Manufacturing, Pharos University, Alexandria, 21311, Egypt
4
Biochemistry Department, Faculty of Science, Alexandria University, Alexandria 21521, Egypt
5
Department of Biochemistry and Molecular Biology, Howard University, College of Medicine, Washington, DC 20059, USA
*
Authors to whom correspondence should be addressed.
Molecules 2016, 21(2), 230; https://doi.org/10.3390/molecules21020230
Submission received: 3 January 2016 / Revised: 1 February 2016 / Accepted: 1 February 2016 / Published: 18 February 2016
(This article belongs to the Section Medicinal Chemistry)
Browse Figures
Versions Notes

Abstract

:
The synthesis of new 3-cyano-2-substituted pyridines bearing various pharmacophores and functionalities at position 2 is described. The synthesized compounds were evaluated for their in vitro anti-cancer activities on five cancer cell lines using 5-FU as reference compound. The results revealed that the benzohydrazide derivative 9a induced growth inhibition in human breast cancer cell line MCF-7 with an IC50 value of 2 μM and it showed lower cytotoxicity on MCF-12a normal breast epithelial cells. Additionally, 9a induced apoptotic morphological changes and induced apoptosis in MCF-7 in a dose and time-dependent manner according to an enzyme linked immunosorbent apoptosis assay which is further confirmed by a TUNEL assay. Flow cytometric analysis indicated that 9a arrested MCF-7 cells in the G1 phase, which was further confirmed by increased expression of p21 and p27 and reduced expression of CDK2 and CDK4. Western blot data revealed significant upregulation of the expression of p53, Bax, caspase-3 and down-regulation of Bcl-2, Mdm-2 and Akt. Additionally, 9a increased the release of cytochrome c from mitochondria to cytoplasm which provokes the mitochondrial apoptotic pathway while it showed no significant change on the expression of the death receptor proteins procaspase-8, caspase-8 and FAS. Furthermore, 9a reduced the expression of phospho AKT and β-catenin in dose dependent manner while inhibiting the expression of migration-related genes such as matrix metalloproteinase (MMP)-9 and vascular endothelial growth factor (VEGF). Our findings suggest that compound 9a could be considered as a lead structure for further development of more potent apoptosis inducing agents with anti-metastatic activities.

Graphical Abstract

1. Introduction

Breast cancer is a complex disease that comprises heterogenous tumors associated with distinctive histological patterns and different clinical characteristics [1]. An estimated 1.7 million women will be diagnosed with breast cancer in 2020, a 26% increase from current levels [2]. Approximately 30% of the women diagnosed with early-stage disease subsequently progress to metastatic breast cancer (MBC), for which few therapeutic regimens exist [3]. Many factors contribute to the metastasis of tumor cells; these include molecular signaling pathways, and expression of metastasis-related genes such as matrix metalloproteinases (MMPs) [4]. Despite the advances in therapeutic modalities, MBC remains incurable, with an estimated survival rate of about 23% over 5 years [5]. Chemotherapy resistance is also a consistent obstacle in the management of breast cancer, where many of the initially responsive tumors relapse and develop resistance to diverse chemotherapeutic agents [6]. Consequently, new agents with low susceptibility to common drug resistance mechanisms are urgently needed for the management and treatment of various forms of breast cancer.
The anticancer activity of most cytotoxic therapies which are currently used in the clinical management of cancer patients including radiotherapy is based on their ability to induce cell death programs such as apoptosis [7]. Apoptosis is an evolutionary conserved process characterized by a series of morphological and biochemical changes, including cell shrinkage, nuclear DNA fragmentation and membrane blebbing [8].
Pyridine derivatives have always constituted a subject of great interest due to the ubiquity of pyridine in Nature and the extensive presence in the skeletal backbone of many therapeutic agents. These derivatives were reported to possess cytotoxic [9], and anticancer activities [10,11,12,13,14,15,16,17,18] in addition to topoisomerase I, II [19,20,21] and Src inhibitory activities [22,23,24]. Penclomedine (PEN1, 3,5-dichloro-4,6-dimethoxy-2-trichloromethylpyridine), is an antitumor agent which was selected for clinical development by the NCI based on its selective antitumor activity against certain carcinomas [25]. Moreover, triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone) is a potent ribonucleotide reductase inhibitor that has shown potent antiproliferative activity against several cancer cell lines [26]. Furthermore, particular interest has been focused on pyridine carbonitriles due to their remarkable in vitro anticancer activity against a wide range of cell lines (Figure 1) [27,28,29,30]. Consequently, pyridine carbonitrile remains a promising template for the design of a new category of chemotherapeutic agents.
Inspired by the abovementioned findings and in continuation of our efforts linked to discovering and exploring novel lead heterocyclic structures as potent chemotherapeutic agents [31,32,33,34], new derivatives of 3-cyano-2-substituted pyridines were synthesized for evaluation of their in vitro anticancer activity. A literature survey revealed that incorporation of alkoxy substituents (methoxy and/or aryloxy moieties) results in significant enhancement of antitumor activity due to magnification of compounds’ lipophilicity [35,36]. Accordingly, the target compounds were designed so as to comprise 3,4-dimethoxyphenyl groups at positions 4 and 6. Moreover to the best of our knowledge, 2-substituted alkoxycyanopyridines are seldom reported in the literature. Therefore, it was planned to include variable substituents at position 2, linked to the cyanopyridine scaffold through a methyleneoxy or acetyloxy spacer (A and B, Figure 1). Such substituents were selected so as to offer variable electronic, lipophilic and steric environment that could influence the targeted biological activity. The substituents include either alkyl groups of different length or biologically active pharmacophores that are believed to be responsible for the biological significance of some reported anticancer agents such as benzohydrazides [37,38] benzosulfohydrazides [10], dithioates [39,40] and arylhydrazones [41,42,43]. In addition, incorporation of heterocyclic groups such as pyrazoles and 1,3,4-oxadiazoles (B, Figure 1) was considered as an interesting structure variation that might impose an impact on the potential biological activities owing to their documented chemotherapeutic activity [44,45,46,47,48].The in vitro antiproliferative activity of the newly synthesized compounds was investigated against five cancer cell lines and the effect of the most promising compound on apoptosis and expression of proteins related to cell cycle pathways was also evaluated.

2. Results and Discussion

2.1. Chemistry

The synthetic strategies adopted for the synthesis of the intermediate and target compounds are depicted in Scheme 1, Scheme 2 and Scheme 3. In Scheme 1, the cyanopyridinone 3 was prepared according to the Al-Saadi procedure [49] via a one-pot multicomponent reaction of 3,4-dimethoxybenzaldehyde (1), 3,4-dimethoxyacetophenone (2), an excess of ammonium acetate and ethyl cyanoacetate in boiling ethanol. Heating the cyanopyridinone 3 with different alkyl halides in absolute ethanol using sodium ethoxide as a basic catalyst according to the Kornblum procedure [50] failed to afford the target O-alkylated derivatives 4a–d. However, such compounds were successfully prepared by heating the cyanopyridinone 3 with the appropriate alkyl halide in acetone in the presence of anhydrous K2CO3. Similarly, refluxing 3 with ethyl bromoacetate in dry acetone containing anhydrous K2CO3 yielded the corresponding ethyl acetate ester 5. Reaction of the ester 5 with hydrazine hydrate in refluxing ethanol resulted in the formation of the corresponding acetohydrazide 6 which was employed as key intermediate for synthesis of the target compounds presented in Scheme 2.
In Scheme 2, the hydrazide 6 was conveniently converted to the dithioate esters 7a–d by reaction with carbon disulfide in DMF in presence of KOH, followed by addition of the appropriate alkyl halide at room temperature. Condensation of the hydrazide 6 with the appropriate aldehyde in boiling ethanol containing few drops glacial acetic acid afforded the respective azomethines 8a–c. It should be noted down here that compounds having the arylidene–hydrazide structure may exist as E/Z geometrical isomers about the C=N bond and as cis/trans amide conformers at the CO–NH moiety (Figure 2) [51,52]. In this respect, the 1H-NMR spectra of these compounds in DMSO-d6 confirmed their existence as E geometrical isomers, which coincides with the literature findings for analogous compounds containing the imine (C=N) functionality [52]. On the other hand, further interpretation of their 1H-NMR DMSO-d6 spectra revealed the presence of three sets of signals at δ 5.09–5.11, 5.60–5.63, 7.96–8.0, 8.18–8.22 and δ 11.58–11.76, 11.62–11.80, attributed to the OCH2, N=CH and CO–NH groups of the cis and trans conformers, respectively. According to the literature, the upfield signals of the N=CH and CONH protons were assigned to the cis conformer of the amide structure, whereas, the downfield peaks were due to the trans conformer [53]. Treatment of the hydrazide 6 with benzoyl chloride or p-methoxybenzoyl chloride in pyridine at room temperature furnished the corresponding benzohydrazides 9a,b. Similarly, reaction of 6 with benzenesulfonyl chloride or p-methoxy-benzenesulfonyl chloride gave rise to the corresponding benzenesulfohydrazides 10a,b in good yield.
In Scheme 3, condensation of the hydrazide 6 with acetylacetone or ethyl acetoacetate in ethanol/glacial acetic acid mixture (2:1) furnished the corresponding 3,5-dimethylpyrazole 11 and the pyrazolinone derivative 12, respectively. Heating 6 with methyl 2-cyano-3,3-bis(methyl-sulfanyl)acrylate or [bis(methylsulfanyl)methylene]malononitrile in dry DMF following reported reaction conditions [54] yielded the proposed 5-amino-3-methylsulfanyl-4-substituted pyrazolyl derivatives 13a,b in moderate yield. On the other hand, refluxing 6 with carbon disulphide in ethanolic potassium hydroxide afforded the oxadiazolyl derivative 14.

2.2. Biological Evaluation

2.2.1. Effect of the Synthesized Compounds on Cell Viability of Different Cancer Cell Lines

The synthesized compounds were screened for their cytotoxicity on five cancer cell lines, namely SK-OV-3, MCF-7, MDA-MB-231, HCT-116 and RKO, using a WST colorimetric assay. The assay principle is based upon the reduction of the tetrazolium salt WST-1 to formazan by cellular mitochondrial dehydrogenases present in viable cells. The results revealed that most of the tested compounds showed higher cytotoxicity than 5-FU on SK-OV-3 cells and among them compound 7c was the most potent as it displayed an IC50 value of 5.12 μM compared to 5-FU which showed an IC50 value of 32.19 μM. Meanwhile, compound 9a (IC50 = 2.04 μM) was more potent than 5-FU (IC50 = 7.06 μM) against MCF-7 cells, whereas compounds 7c and 10b (IC50 = 7.1 and 8.12 μM, respectively) were nearly equipotent to 5-FU. Concerning the activity against MDA-MB-231, none of the test compounds showed remarkable effect on the viability of MDA-MB 231 cells. Moreover, the obtained data showed that compounds 4c, 4d, 7b, 7d and 9a displayed a significant effect (IC50 = 7.12–13.14 μM) on the viability of HCT-116 cells compared to 5-FU and among them compound 9a displayed the highest activity as it showed an IC50 value of 7.12 μM compared to 5-FU which showed an IC50 value of 12.19 μM. Additionally, 9a and 9b (IC50 = 8.22 and 9.95 μM, respectively) were more potent than 5-FU (IC50 = 20.18 μM) on RKO cells (Table 1). Taking the IC50 values as reliable criteria for comparison of cytotoxicity of the test compounds, it could be clearly recognized that cyanopyridines attached to heterocyclic moieties at the 2-position through acetyloxy or methyleneoxy spacers (compounds 11–14) were nearly inactive compared to cyanopyridines attached to alkyl, dithioate, arylhydrazone, benzohydrazide or benzosulfohydrazide groups (compounds 4–10) which showed sigificant cytotoxicity on the tested cell lines. Among the latter compounds the benzohydrazide derivative 9a emerged with the lowest IC50 in this study against MCF-7 cells compared to 5-FU. The level of cytotoxicity of compound 9a on MCF-12a normal breast epithelial cells was also investigated and the IC50 was found to be 7.5 ± 0.25 μM. Moreover, MCF-12a cells were treated with 2 μM 9a for 24 h and the results (Figure 3) indicated that 2 μM of 9a reduced cell viability to approximately 50% in MCF-7 cells compared to approximately 74% in MCF-12a cells. The significance of viability between MCF-7 and MCF-12a cells was calculated using SPSS non-parametric analysis of two independent tests and the results showed statistical significance of p value 0.001. Based on the fact that 9a had less cytotoxic effects on normal breast epithelial cells it was subjected to further studies.

2.2.2. Compound 9a induces apoptosis in MCF-7 cells

Morphological Changes

The morphological changes in MCF-7 cells were followed up after treatment with different concentrations of compound 9a (0.05, 0.1, 0.5, 2, 5 and 10 μM) for 24 h. At 0.05, 0.1 and 0.5 μM, no morphological changes were observed, however upon treating the cells with higher concentrations of 2, 5 and 10 μM, apoptotic features were observed, including marked apoptotic bodies and cell shrinkage in a concentration dependent manner (Figure 4A). Untreated cells were used as a negative control. Treatment of MCF-7 cells with DMSO 0.4% did not show any characteristics of apoptosis in the MCF-7 cells.

TUNEL Assay

To ascertain induction of apoptosis of compound 9a on MCF-7 cells, the results were confirmed by immune histochemical analysis using a TUNEL assay. TUNEL assay involves labeling of the 3'-hydroxyl DNA ends generated during DNA fragmentation by means of rTdT and labeled dUTP. The localized fluorescence of apoptotic cells (labeled-dUTP) in a blue background (DAPI) for nuclei staining or green background (FITC) was visualized using fluorescence microscope. The assay results (Figure 4B) revealed the presence of nuclear condensation and TUNEL-positive cells (stained cells) compared to control group.

Enzyme Linked Immunosorbent Apoptosis Assay

Compound 9a was further investigated for induction of apoptosis in MCF-7 cells using Cell Death Detection ELISAPLUS which is used for the quantitative in vitro determination of cytoplasmic histone-associated DNA fragments (mono- and oligonucleosomes) in apoptosing cells.
The results revealed that induction of apoptosis increased in a dose dependent fashion upon treating MCF-7 cells with different concentrations of 9a ranging from 0.1 to 4 μM (Figure 4C-i), additionally, apoptotic induction in MCF-7 cells increases with increasing the exposure time starting from 3 h to 48 h (Figure 4C-ii) with optimum value at 24 h.

Flow Cytometric Analysis

Flow cytometry is considered one of the specific tools for the investigation of molecular and morphological events occurring during cell death and cell proliferation [55]. Therefore, the effect of compound 9a on cell cycle progression was studied by flow cytometry in propidium iodide (PI) stained cells. The percent of cells in G1, S, G2 phases was determined after treating cells with 2 μM of 9a for 24 h (Figure 4D). The results revealed a significant increase in the percent of G1 population (54%) compared to control group (37%). Thus, it can be concluded that compound 9a inhibits the proliferation of MCF-7 cells and the growth inhibition is associated with induction of G1 phase arrest. p27 is considered as an important regulator of cell cycle [56]. To determine whether compound 9a-induced G1 arrest was associated with increased p27 level, and to study the effect on the expression of CDK2 and CDK4 involved in cell cycle progression, cells were analyzed for the expression of these proteins using western blot analysis after treatment with 2 μM of 9a for 24 h. The results (Figure 4E) revealed that compound 9a increased the expression of p27 and decreased the expression of both CDK2 and CDK4.

Impact of 9a on Apoptotic Signaling Pathways

To further investigate the underlying pathways of 9a-induced apoptosis, we evaluated the expression of some apoptotic and survival proteins involved in apoptosis such as p53, p21, Bax and antiapoptotic proteins such as Bcl-2 in addition to protein kinases e.g., AKT. The tumor suppressor protein p53 plays a critical role in inducing cell cycle arrest or apoptosis through its transcriptional activity [57]. Activation of p53 induces expression of cell cycle regulators such as p21WAF1 which is considered as an important regulator of cell cycle [58]. Moreover, activation of p53 leads to activation of the intrinsic pathway by increasing the expression of many pro-apoptotic proteins such as Bax and Bid. After reception of the death signal, Bax; a Bcl-2 family protein, induces cell death through disruption of mitochondrial permeability and subsequent release of cytochrome c where it engages in a cascade of interactions that leads to the execution stage of apoptosis [59]. In this study, the obtained results revealed that compound 9a increased the level of p53, p21 and Bax in MCF-7 cells treated with the IC50 (2 μM) of compound 9a for 24 h compared with untreated cells used as a control (Figure 5A). It is known that interactions between the pro- and antiapoptotic members of Bcl-2 family integrate diverse upstream signals to determine the cellular response. Apoptosis occurs through competitive dimerization between the two protein groups [60]. Accordingly, an increased ratio of Bax to Bcl-2 leads to programmed cell death. Therefore, we analyzed the level of Bcl-2 protein following treatment of MCF-7 cells with 2 μM 9a for 24 h and the obtained data portrayed that the level of Bcl-2 protein was decreased (Figure 5B). Mouse Double Minute 2 Homolog (MDM2) and Akt are negative regulators of p53 and the apoptotic process. Therefore, we evaluated the effect of 9a on these regulators. The obtained data showed that 9a decreased levels of both MDM2 and Akt (Figure 5B). Cytochrome c, a component of the mitochondrial electron transfer chain, is released into the cytosol during the early phases of apoptosis. Therefore the accumulation of mitochondrial cytochrome c release in the cytosol was determined by immunoblotting of the cell lysate of 9a treated cells. Data from western blot analysis (Figure 5C) showed that treatment of MCF-7 cells with 2 μM 9a for 24 h increased the expression of cytochrome c in cytoplasm and reduced its expression in mitochondria (Figure 5C). In order to investigate whether compound 9a induces caspase-dependent or independent cascade we have also studied the expression of caspase-3. Caspase 3 is activated by procaspase 3, therefore the pro form and the active form of caspase 3 constitute a useful biomarker to confirm apoptosis. The results of the current study revealed that compound 9a decreased the level of procaspase 3 and up-regulated the expression of caspase-3 in MCF-7 cells treated for 24 h with 2 μM 9a (Figure 5D).To assess the alterations of apoptosis-related death receptor protein levels in MCF-7 cells, the expression of FAS, procaspase-8 and caspase-8 was evaluated by western blot analysis.
As shown in Figure 5E, there was no significant change in the expression of these proteins in treated and untreated groups.

The Effect of 9a on the Expression of Angiogenesis-Related Genes

AKT is a serine/threonine protein kinase that plays a key role in multiple cellular processes including metabolism, proliferation, apoptosis/survival, and migration. Phosphorylation of Akt at S473 activates Akt which is involved in the angiogenic process [61]. On the other hand, the WNT/β-catenin signaling pathway plays an important role in carcinogenesis and tumor metastasis, in many cancer types including breast cancer [62]. Therefore, we further investigated the possible effects of compound 9a on the expression of phospho AKT and β-catenin. Our data clearly revealed that 9a reduced the expression of phospho AKT and β-catenin in dose-dependent manner (Figure 6A). The angiogenic response is induced by growth factors such as VEGF, basic fibroblast growth factor (bFGF), platelet-derived growth factor (PDGF), and chemokines. Matrix metallopeptidases (MMPs) such as MMP9 plays an important role in extracellular matrix remodeling, angiogenesis and metastasis and its increased expression was observed in a metastatic mammary cancer cell line [63]. In the present study, the data (Figure 6B) revealed that compound 9a significantly inhibited expression of VEGF and MMP-9 in MCF-7 cells.

3. Experimental Section

3.1. General Informstion

Melting points were determined in open-glass capillaries using Stuart capillary melting point apparatus (Stuart Scientific Stone, Staffordshire, UK) and are uncorrected. The IR spectra (KBr) were recorded using a Perkin-Elmer 1430 spectrophotometer (Perkin Elmer, Beaconsfield, UK). The 1H-NMR and 13C-NMR spectra were determined on a Mercury VX-300 MHz spectrometer (Varian, San Diego, CA, USA) using tetramethylsilane (TMS) as internal standard and DMSO-d6 as solvent (chemical shifts are given in δ ppm). Mass spectra were run on a GCMS-QP 2010 Plus (70 eV) gas chromatograph/mass spectrometer (Shimadzu, Kyoto, Japan). Microanalyses were performed at the Regional Center for Mycology and Biotechnology, El-Azhar University (Cairo, Egypt). The microanalyses results were within ±0.4% of the calculated values. Monitoring of reactions and checking the purity of the compounds was done by thin layer chromatography (TLC) on silica gel-precoated aluminium sheets (Type 60 GF254; Merck, Munich, Germany) and the spots were detected by exposure to UV lamp at λ 254 nm for a few seconds.

3.2. Chemistry

3.2.1. 4,6-bis(3,4-Dimethoxyphenyl)-2-oxo-1,2-dihydropyridine-3-carbonitrile (3)

A mixture of 3,4-dimethoxybenzaldehyde 1 (1.66 g, 0.01 mol), 3,4-dimethoxyacetophenone 2 (1.8 g, 0.01 mol), ethyl cyanoacetate (1.13 g, 0.01 mol) and anhydrous ammonium acetate (7.71 g, 0.1 mol) in ethanol (50 mL) was stirred and heated under reflux for 12 h. The reaction mixture was allowed to cool and the obtained precipitate was filtered, washed with cold ethanol, dried and crystallized from dimethyl formamide/ethanol (2:1). Yield: 70%, m.p.: 180–182 °C. IR (ν cm−1): 3455 (NH), 2216 (CN), 1653 (C=O), 1267, 1021 (C-O-C). 1H-NMR (ppm): 3.84 (s, 6H, 2 OCH3), 3.87 (s, 6H, 2 OCH3), 6.83 (s, 1H, pyridine C5-H), 7.09 (d, J = 8.7 Hz, 1H, dimethoxyphenyl C5-H), 7.14 (d, J = 9.0 Hz, 1H, dimethoxyphenyl C5-H), 7.33 (s, 1H, dimethoxyphenyl C2-H), 7.35 (s, 1H, dimethoxyphenyl C2-H), 7.47 (d, J = 8.7 Hz, 1H, dimethoxyphenyl C6-H), 7.53 (d, J = 9.0 Hz, 1H, dimethoxyphenyl C6-H), 12.25 (s, 1H, NH). Anal. Calcd (%) for C22H20N2O5 (392.4): C, 67.34; H, 5.14; N, 7.14. Found: C, 67.09; H, 5.11; N, 6.99.

3.2.2. General Procedure for the Synthesis of Compounds 4a–d

To a solution of the cyanopyridone 3 (0.39 g, 0.001 mol) in dry acetone (5 mL) containing anhydrous potassium carbonate (0.14 g, 0.001 mol), the appropriate alkyl halide or chloroacetone (0.001 mol) was added dropwise. The reaction mixture was stirred and heated under reflux for 2 h then allowed to attain room temperature. It was then poured onto crushed ice and the separated solid product was filtered, washed with water, dried and crystallized from the proper solvent.
2-Methoxy-4,6-bis(3,4-dimethoxyphenyl)pyridine-3-carbonitrile (4a). Yield: 72%, m.p.: 155–156 °C (ethanol). IR (ν cm−1): 2213 (CN), 1586 (C=N), 1263, 1223, 1024 (C-O-C). 1H-NMR (ppm): 3.71 (s, 3H, OCH3), 3.73 (s, 3H, OCH3), 3.79 (s, 3H, OCH3), 3.81 (s, 3H, OCH3), 3.83 (s, 3H, OCH3), 6.98 (d, J = 8.7 Hz, 1H, dimethoxyphenyl C5-H), 7.07 (d, J = 8.4 Hz, 1H, dimethoxyphenyl C5-H), 7.31–7.37 (m, 2H, dimethoxyphenyl C2,6-H), 7.75 (s, 1H, pyridine C5-H), 7.78 (d, J = 2.1 Hz, 1H, dimethoxyphenyl C2-H), 7.79 (d, J =8.4, 2.1 Hz, 1H, dimethoxyphenyl C6-H). 13C-NMR (DMSO-d6, ppm): 55.36, 55.42, 55.56, 55.60, 55.64, 90.46, 110.12, 111.74, 111.79, 111.89, 113.13, 115.69, 120.64, 121.56, 127.83, 128.91, 148.59, 148.81, 150.23, 151.12, 156.10, 156.69, 163.08. Anal. Calcd (%) for C23H22N2O5 (406.43): C, 67.97; H, 5.46; N, 6.89. Found: C, 68.13; H, 5.44; N, 7.03.
2-Ethoxy-4,6-bis(3,4-dimethoxyphenyl)pyridine-3-carbonitrile (4b). Yield: 73%, m.p.: 152–153 °C (ethanol). IR (ν, cm−1): 2220 (CN), 1582 (C=N), 1265, 1226, 1027 (C-O-C). 1H-NMR (ppm): 1.44 (t, J = 6.9 Hz, 3H, CH3), 3.84 (s, 3H, OCH3), 3.85 (s, 3H, OCH3), 3.86 (s, 3H, OCH3), 3.87 (s, 3H, OCH3), 4.62 (q, J = 6.9 Hz, 2H, OCH2), 7.10 (d, J = 8.9 Hz, 1H, dimethoxyphenyl C5-H), 7.15 (d, J = 8.3 Hz, 1H, dimethoxyphenyl C5-H), 7.29–7.35 (m, 2H, dimethoxyphenyl C2,6-H), 7.75 (s, 1H, pyridine C5-H), 7.78 (d, J = 2.1 Hz, 1H, dimethoxyphenyl C2-H), 7.80 (dd, J = 8.3, 2.1 Hz, 1H, dimethoxyphenyl C6-H). 13C-NMR (ppm): 14.8, 55.45, 55.58, 55.59, 55.66, 63.88, 90.49, 110.14, 111.73, 111.77, 111.94, 113.18, 115.72, 120.73, 121.64, 127.94, 129.01, 148.66, 148.84, 150.19, 151.18, 156.21, 156.82, 163.22. EI-MS m/z (%): 420.17 (M+) (77 %), 111 (100%). Anal. Calcd (%) for C24H24N2O5 (420.46): C, 68.56; H, 5.75; N, 6.66. Found: C, 68.72; H, 5.78; N, 6.79.
4,6-bis(3,4-Dimethoxyphenyl)-2-propoxypyridine-3-carbonitrile (4c). Yield: 64%, m.p.: 156–158 °C (dimethylformamide/ethanol 2:1). IR (ν cm−1): 2214 (CN), 1583 (C=N), 1264, 1228, 1026 (C-O-C). 1H-NMR (ppm): 0.93 (t, J = 6.9 Hz, 3H, CH2CH3), 1.65–1.70 (m, 2H, CH2CH3), 3.77 (s, 3H, OCH3), 3.80 (s, 3H, OCH3), 3.82 (s, 3H, OCH3), 3.84 (s, 3H, OCH3), 4.83 (t, J = 6.9 Hz, 2H, OCH2), 6.96 (d, J = 8.3 Hz, 1H, dimethoxyphenyl C5-H), 7.08 (d, J = 8.5 Hz, 1H, dimethoxyphenyl C5-H), 7.22 (dd, J = 8.3, 1.8 Hz, 1H, dimethoxyphenyl C6-H), 7.26 (d, J = 1.8 Hz, 1H, dimethoxyphenyl C2-H), 7.67 (s, 1H, pyridine C5-H), 7.70 (d, J = 1.8 Hz, 1H, dimethoxyphenyl C2-H), 7.77 (dd, J = 8.5, 1.8 Hz, 1H, dimethoxyphenyl C6-H). 13C-NMR (ppm): 11.76, 23.84, 55.49, 55.55, 55.61, 55.68, 65.23, 90.56, 110.22, 111.65, 111.82, 112.12, 113.33, 115.68, 120.80, 121.66, 128.01, 129.14, 148.73, 148.69, 150.26, 151.34, 156.27, 156.94, 163.25. Anal. Calcd (%) for C25H26N2O5 (434.48): C, 69.11; H, 6.03; N, 6.45. Found: C, 68.77; H, 5.73; N, 6.59.
4,6-bis(3,4-Dimethoxyphenyl)-2-(2-oxopropoxy)pyridine-3-carbonitrile (4d). Yield: 75%, m.p.: 110–112 °C (ethanol). IR (ν cm−1): 2214 (CN), 1731 (C=O), 1593 (C=N), 1262, 1023 (C-O-C). 1H-NMR (ppm): 2.23 (s, 3H, COCH3), 3.72 (s, 3H, OCH3), 3.78 (s, 3H, OCH3), 3.80 (s, 3H, OCH3), 3.83 (s, 3H, OCH3), 5.25 (s, 2H, OCH2), 7.08 (d, J = 8.7 Hz, 1H, dimethoxyphenyl C5-H), 7.17 (d, J = 8.4 Hz, 1H, dimethoxyphenyl C5-H), 7.33 (dd, J = 8.7 Hz, 2.1 Hz, 1H, dimethoxyphenyl C6-H), 7.37 (d, J = 2.1 Hz, 1H, dimethoxyphenyl C2-H), 7.66 (s, 1H, pyridine C5-H), 7.77 (d, J = 8.4 Hz, 1H, dimethoxyphenyl C6-H), 7.78 (d, J = 2.1 Hz, 1H, dimethoxyphenyl C2-H). 13C-NMR (ppm):25.73, 55.47, 55.54, 55.57, 55.62, 70.62, 90.42, 110.07, 111.63, 111.71, 111.92, 113.05, 115.66, 120.75, 121.50, 127.87, 128.84, 148.54, 148.76, 150.29, 151.06, 156.07, 156.64, 162.96, 203.32. Anal. Calcd (%) for C25H24N2O6 (448.47): C, 66.95; H, 5.39; N, 6.25. Found: C, 67.15; H, 5.44; N, 6.21.

3.2.3. Ethyl 2-(3-Cyano-4,6-bis(3,4-dimethoxyphenyl)pyridin-2-yloxy)acetate (5)

A mixture of 3 (3.92 g, 0.01 mol), ethyl bromoacetate (1.67 g, 0.01 mol) and anhydrous potassium carbonate (5.53 g, 0.04 mol) in dry acetone (30 mL) was heated under reflux for 20 h. After cooling, water was added and the reaction mixture was left in a refrigerator for an overnight. The separated solid product was filtered, washed with water, dried and recrystallized from ethanol. Yield: 72%, m.p.: 130–132 °C. IR (ν cm−1): 2220 (CN), 1760 (C=O), 1595 (C=N), 1258, 1231, 1067, 1028 (C-O-C). 1H-NMR (ppm): 1.15 (t, J = 7.1 Hz, 3H, CH2CH3), 3.84 (s, 3H, OCH3), 3.85 (s, 3H, OCH3), 3.86 (s, 6H, 2OCH3), 4.17 (q, J = 7.1 Hz, 2H, CH2CH3), 5.14 (s, 2H, OCH2), 7.08 (d, J = 8.4 Hz, 1H, dimethoxyphenyl C5-H), 7.16 (d, J = 8.3 Hz, 1H, dimethoxyphenyl C5-H), 7.32–7.38 (m, 2H, dimethoxyphenyl C2,6-H), 7.73 (d, J = 1.9 Hz, 1H, dimethoxyphenyl C2-H), 7.81 (dd, J = 8.3, 1.9 Hz, 1H, C6-H), 7.84 (s, 1H, pyridine C5-H). 13C-NMR (ppm):13.88, 55.51, 55.63, 55.59, 55.63, 60.81, 63.61, 90.45, 110.34, 111.57, 111.72, 111.99, 113.12, 115.52, 120.79, 121.53, 127.82, 128.66, 148.58, 148.78, 150.35, 151.22, 156.21, 156.47, 162.82, 168.51. Anal. Calcd (%) for C26H26N2O7 (478.49): C, 65.26; H, 5.48; N, 5.85. Found: C, 65.38; H, 5.53; N, 5.97.

3.2.4. 2-{[3-Cyano-4,6-bis(3,4-dimethoxyphenyl)pyridin-2-yl]oxy}acetohydrazide (6)

To a suspension of 5 (4.8 g, 0.01 mol) in absolute ethanol (50 mL), hydrazine hydrate 98% (3.2 g, 0.1 mol) was added. The reaction mixture was heated under reflux for 8 h then allowed to cool to room temperature. The obtained product was filtered, washed with ethanol, dried and recrystallized from ethyl alcohol/dimethylformamide mixture (3:1). Yield: 68%, m.p.: 216–218°C. IR (ν cm−1): 3437, 3303 (NH), 2209 (CN), 1690 (C=O), 1645 (C=N), 1268, 1019 (C-O-C). 1H-NMR (ppm): 3.83 (s, 3H, OCH3), 3.85 (s, 3H, OCH3), 3.86 (s, 3H, OCH3), 3.88 (s, 3H, OCH3), 4.27 (s, 2H, NH2, D2O exchangeable), 4.97 (s, 2H, OCH2), 7.07 (d, J = 8.7 Hz, 1H, dimethoxyphenyl C5-H), 7.17 (d, J = 8.8 Hz, 1H, dimethoxy-phenyl C5-H), 7.29–7.35 (m, 2H, dimethoxyphenyl C2,6-H), 7.75 (d, J = 2.0 Hz, 1H, dimethoxyphenyl C2-H), 7.80 (s, 1H, pyridine C5-H), 7.82 (dd, J = 8.8, 2.0 Hz, 1H, dimethoxyphenyl C6-H), 9.36 (s, 1H, NH). 13C-NMR (ppm): 55.54, 55.66, 55.56, 55.67, 63.65, 90.44, 110.38, 111.63, 111.70, 112.22, 113.16, 115.56, 120.77, 121.55, 127.88, 128.74, 148.68, 148.82, 150.42, 151.26, 156.18, 156.51, 162.85, 168.46. Anal. Calcd (%) for C24H24N4O6 (464.47): C, 62.06; H, 5.21; N, 12.06. Found: C, 62.29; H, 5.28; N, 12.12.

3.2.5. General Procedure for the Synthesis of Compounds 7a–d

To a well stirred cold suspension of fine powdered potassium hydroxide (0.11 g, 0.002 mol) in dimethylformamide (4 mL) the acid hydrazide 6 (0.46 g, 0.001 mol) was added followed by carbon disulphide (0.076 g, 0.001 mol). The reaction mixture was stirred at room temperature overnight then the appropriate alkyl halide (0.001 mol) was added and the mixture was further stirred at room temperature for 12 h. The reaction mixture was concentrated under reduced pressure then poured into ice-cold water and the obtained precipitate was filtered, washed with water, dried and crystallized from ethanol.
Methyl 2-[2-(3-cyano-4,6-bis(3,4-dimethoxyphenyl)pyridin-2-yloxy)acetyl]hydrazinecarbodithioate (7a). Yield: 63%, m.p.:151–153 °C. IR (ν cm−1): 3433 (NH), 2214 (CN), 1675 (C=O), 1589 (C=N), 1516, 1314, 1145, 977 (NCS), 1261, 1023 (C-O-C). 1H-NMR (ppm): 2.69 (s, 3H, SCH3), 3.84 (s, 3H, OCH3), 3.85 (s, 3H, OCH3), 3.86 (s, 3H, OCH3), 3.91 (s, 3H, OCH3), 5.78 (s, 2H, OCH2), 7.07 (d, J = 8.7 Hz, 1H, dimethoxyphenyl C5-H), 7.16 (d, J = 8.4 Hz, 1H, dimethoxyphenyl C5-H), 7.32–7.38 (m, 2H, dimethoxyphenyl C2,6-H), 7.80 (d, J = 1.8 Hz, 1H, dimethoxyphenyl C2-H), 7.84–7.88 (m, 2H, dimethoxyphenyl C6-H and pyridine C5-H), 10.40 (s, 1H, NH), 10.59 (s, 1H, NH). 13C-NMR (ppm):16.28, 55.67, 58.14, 64.21, 91.25, 110.37, 111.59, 111.77, 112.22, 113.62, 115.39, 120.84, 121.56, 127.85, 128.72, 148.63, 148.90, 150.42, 151.31, 156.29, 156.74, 162.44, 164.60, 172.26. EI-MS m/z (%): 554 (M+) (19.5 %), 94 (100%). Anal. Calcd (%) for C26H26N4O6S2 (554.64): C, 56.30; H, 4.72; N, 10.10. Found: 56.38; H, 4.75; N, 10.21.
Ethyl 2-[2-(3-cyano-4,6-bis(3,4-dimethoxyphenyl)pyridin-2-yloxy)acetyl]hydrazinecarbodithioate (7b). Yield: 64%, m.p.: 144–146 °C. IR (ν cm−1): 3437 (NH), 2214 (CN), 1672 (C=O), 1591 (C=N), 1516, 1307, 1144, 979 (NCS), 1261, 1025 (C-O-C). 1H-NMR (ppm): 1.28 (t, J = 7.1 Hz, 3H, CH3), 3.18 (q, J = 7.1 Hz, 2H, SCH2), 3.76 (s, 3H, OCH3), 3.82 (s, 3H, OCH3), 3.83 (s, 3H, OCH3), 3.88 (s, 3H, OCH3), 5.83 (s, 2H, OCH2), 7.07 (d, J = 9.0 Hz, 1H, dimethoxyphenyl C5-H), 7.16 (d, J = 8.1 Hz, 1H, dimethoxyphenyl C5-H), 7.28-7.32 (m, 2H, dimethoxyphenyl C2,6-H), 7.73–7.86 (m, 3H, dimethoxyphenyl C2,6-H and pyridine C5-H), 10.42 (s, 1H, NH), 10.63 (s, 1H, NH). 13C-NMR (ppm): 14.54, 26.61, 55.64, 58.07, 63.98, 90.78, 110.49, 111.56, 111.74, 112.14, 113.58, 115.37, 120.87, 121.54, 127.80, 128.68, 148.61, 148.89, 150.40, 151.24, 156.33, 156.70, 162.41, 163.78, 171.98. Anal. Calcd (%) for C27H28N4O6S2 (568.66): C, 57.03; H, 4.96; N, 9.85. Found: C, 57.17; H, 4.92; N, 9.91.
2-Morpholinoethyl-2-[2-(3-cyano-4,6-bis(3,4-dimethoxyphenyl)pyridin-2-yloxy)acetyl]hydrazinecarbo-dithioate (7c). Yield: 66 %, m.p.: 158–160 °C. IR (ν, cm−1): 3435 (NH), 2217 (CN), 1656 (C=O), 1586 (C=N), 1516, 1322, 1138, 921 (NCS), 1262, 1022 (C-O-C). 1H-NMR (ppm): 2.60–2.64 (m, 4H, morpholine C3,5-H2), 2.74 (t, J = 6.9 Hz, 2H, SCH2), 2.94 (t, J = 6.9 Hz, 2H, NCH2), 3.59–3.64 (m, 4H, morpholine C2,6-H2), 3.78 (s, 3H, OCH3), 3.83 (s, 3H, OCH3), 3.84 (s, 3H, OCH3), 3.88 (s, 3H, OCH3), 5.72 (s, 2H, OCH2), 7.06 (d, J = 8.1 Hz, 1H, dimethoxyphenyl C5-H), 7.14 (d, J = 8.4 Hz, 1H, dimethoxyphenyl C5-H), 7.28–7.33 (m, 2H, dimethoxyphenyl C2,6-H), 7.75–7.81 (m, 3H, dimethoxyphenyl C2,6-H and pyridine C5-H), 10.49 (s, 1H, NH), 10.67 (s, 1H, NH). 13C-NMR (ppm): 32.83, 52.10, 55.65, 55.67, 56.13, 58.07, 64.69, 90.73, 110.41, 111.57, 111.72, 113.11, 113.58, 115.36, 120.86, 121.55, 127.80, 128.67, 148.59, 148.89, 150.38, 151.21, 156.37, 156.72, 162.35, 164.30, 172.0. Anal. Calcd (%) for C31H35N5O7S2 (653.77): C, 56.95; H, 5.40; N, 10.71. Found: 56.61; H, 5.18; N, 11.04.
2-(Piperidin-1-yl)-ethyl-2-[2-(3-cyano-4,6-bis(3,4-dimethoxyphenyl)pyridin-2-yloxy)acetyl]hydrazinecarbo-dithioate (7d). Yield: 66 %, m.p.: 160–162 °C. IR (ν, cm−1): 3434 (NH), 2218 (CN), 1645 (C=O), 1587 (C=N), 1516, 1322, 1134, 921 (NCS), 1262, 1022 (C-O-C). 1H-NMR (ppm): 1.44–1.48 (m, 2H, piperidine C4-H2), 1.60–1.64 (m, 4H, piperidine C3,5-H2), 2.83–3.07 (m, 8H, piperidine C2,6-H, SCH2 and NCH2), 3.86 (s, 3H, OCH3), 3.87 (s, 3H, OCH3), 3.90 (s, 3H, OCH3), 3.92 (s, 3H, OCH3), 5.64 (s, 2H, OCH2), 7.08 (d, J = 8.1 Hz, 1H, dimethoxyphenyl C5-H), 7.20 (d, J = 8.4 Hz, 1H, dimethoxyphenyl C5-H), 7.33–7.38 (m, 2H, dimethoxyphenyl C2,6-H), 7.71–7.85 (m, 3H, dimethoxyphenyl C2,6-H and pyridine C5-H), 10.51 (s, 1H, NH), 10.69 (s, 1H, NH). 13C-NMR (ppm): 23.76, 33.14, 52.26, 53.82, 55.65, 55.67, 63.99, 91.33, 110.42, 111.55, 111.76, 113.14, 113.59, 115.54, 120.88, 121.61, 127.84, 128.69, 148.55, 148.93, 150.27, 151.33, 156.44, 156.81, 162.46, 164.42, 174.20. Anal. Calcd (%) for C32H37N5O6S2 (651.8): C, 58.97; H, 5.72; N, 10.74. Found: 58.99; H, 5.83; N, 10.92.

3.2.6. General Procedure for the Synthesis of Compounds 8a–c

A mixture of 6 (0.464 g, 0.001 mol) and the appropriate aldehyde (0.001 mol) in absolute ethanol (20 mL) containing 2 drops of glacial acetic acid was heated under reflux for 8 h. The reaction mixture was allowed to attain room temperature and the separated solid product was filtered, washed with ethanol, dried and recrystallized from dimethylformamide.
2-[3-Cyano-4,6-bis(3,4-dimethoxyphenyl)pyridin-2-yl]oxy-N'-(4-methoxybenzylidene)acetohydrazide (8a). Yield: 84%, m.p.: 163–164 °C. IR (ν, cm−1): 3189 (NH), 2224 (CN), 1673 (C=O), 1601 (C=N), 1257, 1026 (C-O-C). 1H-NMR (ppm):3.64 (s, 3H, OCH3), 3.78 (s, 3H, OCH3), 3.80 (s, 3H, OCH3), 3.86 (s, 3H, OCH3), 3.88 (s, 3H, OCH3), 5.09 (s, 2H, OCH2, cis conformer), 5.60 (s, 2H, OCH2, trans conformer), 6.95–7.03 (m, 3H, dimethoxyphenyl C5-H and methoxyphenyl C3,5-H), 7.18 (d, J = 8.4 Hz, 1H, dimethoxyphenyl C5-H), 7.33–7.37 (m, 2H, dimethoxyphenyl C2,6-H), 7.62–7.72 (m, 4H, dimethoxyphenyl C2,6-H and methoxyphenyl C2,6-H), 7.79 (s, 1H, pyridine C5-H), 8.0 (s, 1H, N=CH, cis conformer), 8.22 (s, 1H, N=CH, trans conformer), 11.58 (s, 1H, NH, cis conformer), 11.62 (s, 1H, NH, trans conformer). 13C-NMR (ppm): 55.22, 55.51, 55.64, 70.15, 90.45, 109.94, 111.50, 111.76, 112.30, 113.59, 114.29, 115.66, 120.73, 121.48, 127.40, 128.10, 128.33, 128.43, 142.50, 148.55, 148.85, 150.38, 151.19, 155.80, 156.04, 160.75, 163.50, 164.34. Anal. Calcd (%) for C32H30N4O7 (582.6): C, 65.97; H, 5.19; N, 9.62. Found: C, 66.12; H, 5.43; N, 9.91.
2-[3-Cyano-4,6-bis(3,4-dimethoxyphenyl)pyridin-2-yl]oxy-N'-(3,4-dimethoxybenzylidene)acetohydrazide (8b).Yield: 82%, m.p.:190–192 °C. IR (ν, cm−1): 3200, 3133 (NH), 2210 (CN), 1696 (C=O), 1581 (C=N), 1264, 1023 (C-O-C). 1H-NMR (DMSO-d6, ppm): 3.66 (s, 3H, OCH3), 3.77 (s, 3H, OCH3), 3.80 (s, 3H, OCH3), 3.82 (s, 3H, OCH3), 3.86 (s, 3H, OCH3), 3.87 (s, 3H, OCH3), 5.11 (s, 2H, OCH2, cis conformer), 5.62 (s, 2H, OCH2, trans conformer), 6.96 (d, J = 8.7 Hz, 1H, dimethoxyphenyl C5-H), 7.16–7.20 (m, 2H, two dimethoxyphenyl C5-H), 7.33–7.79 (m, 6H, three dimethoxyphenyl C2,6-H), 7.98 (s, 1H, pyridine C5-H), 8.0 (s, 1H, N=CH, cis conformer), 8.18 (s, 1H, N=CH, trans conformer), 11.68 (s, 1H, NH, cis conformer), 11.72 (s, 1H, NH, trans conformer). 13C-NMR (ppm): 55.20, 55.45, 55.56, 55.62, 70.26, 90.26, 110.10, 110.85, 111.53, 111.77, 111.96, 113.20, 113.83, 115.74, 120.98, 121.82, 123.50, 127.74, 128.44, 129.12, 144.36, 148.58, 148.80, 149.05, 149.85, 150.32, 151.18, 155.93, 156.34, 163.88, 164.42.EI-MS m/z (%): 612 (M+) (14.34%), 69.0 (100%). Anal. Calcd (%) for C33H32N4O8 (612.63): C, 64.70; H, 5.26; N, 9.15. Found: C, 64.82; H, 5.22; N, 9.23.
2-[3-Cyano-4,6-bis(3,4-dimethoxyphenyl)pyridin-2-yl]oxy-N'-(3,4,5-trimethoxybenzylidene)acetohydrazide (8c). Yield: 79 %, m.p.: 232–234 °C. IR (ν, cm−1): 3204 (NH), 2217 (CN), 1670 (C=O), 1586 (C=N), 1263, 1022 (C-O-C). 1H-NMR (ppm): 3.67 (s, 3H, OCH3), 3.70 (s, 3H, OCH3), 3.78 (s, 3H, OCH3), 3.81 (s, 3H, OCH3), 3.83 (s, 3H, OCH3), 3.86 (s, 3H, OCH3), 3.87 (s, 3H, OCH3), 5.10 (s, 2H, OCH2, cis conformer), 5.63 (s, 2H, OCH2, trans conformer), 6.98 (d, J = 8.7 Hz, 1H, dimethoxyphenyl C5-H), 7.06 (s, 1H, trimethoxyphenyl-H), 7.18 (d, J = 8.1 Hz, 1H, dimethoxyphenyl C5-H), 7.32–7.37 (m, 3H, dimethoxyphenyl-C2,6-H and trimethoxyphenyl-H), 7.71 (d, J = 1.8 Hz, 1H, dimethoxyphenyl C2-H), 7.78–7.81 (m, 2H, pyridine C5-H and dimethoxyphenyl C6-H), 7.96 (s, 1H, N=CH, cis conformer), 8.19 (s, 1H, N=CH, trans conformer), 11.76 (s, 1H, N=H, cis conformer), 11.80 (s, 1H, NH, trans conformer). 13C-NMR (ppm): 55.53, 55.68, 56.33, 56.46, 60.45, 70.37, 90.48, 104.60, 110.08, 110.79, 111.62, 111.88, 112.47, 115.58, 120.98, 121.82, 127.78, 128.52, 130.37, 139.64, 144.64, 148.58, 149.05, 149.85, 150.32, 153.76, 155.88, 157.11, 164.29, 165.12. Anal. Calcd (%) for C34H34N4O9 (642.66): C, 63.54; H, 5.33; N, 8.72. Found: C, 63.59; H, 5.36; N, 8.81.

3.2.7. General Procedure for the Synthesis of Compounds 9a,b and 10a,b

To a suspension of 6 (0.464 g, 0.001 mol) in dry pyridine (5 mL), the appropriate aroyl chloride or sulfonyl chloride (0.001 mol) was slowly added at 0 °C. The reaction mixture was stirred at room temperature overnight then poured into ice-cold water. The obtained precipitate was filtered, washed with water, dried and crystallized from dimethylformamide/ethanol mixture (3:1).
N'-[2-(3-cyano-4,6-bis(3,4-dimethoxyphenyl)pyridin-2-yloxy)acetyl]benzohydrazide (9a). Yield: 67 %, m.p.: 222–224 °C. IR (ν, cm−1): 3416, 3168 (NH), 2216 (CN), 1680 (C=O), 1605 (C=N), 1261, 1025 (C-O-C). 1H-NMR (ppm): 3.84 (s, 3H, OCH3), 3.86 (s, 3H, OCH3), 3.87 (s, 3H, OCH3), 3.89 (s, 3H, OCH3), 5.19 (s, 2H, OCH2), 7.08 (d, J = 8.7 Hz, 1H, dimethoxyphenyl C5-H), 7.18 (d, J = 9.0 Hz, 1H, dimethoxyphenyl C5-H), 7.33–7.76 (m, 2H, dimethoxyphenyl C2,6-H), 7.46–7.57 (m, 3H, phenyl C3,4,5-H), 7.83–7.92 (m, 5H, phenyl C2,6-H, dimethoxyphenyl C2,6-H and pyridine C5-H), 10.41 (s, 1H, NH), 10.50 (s, 1H, NH). 13C-NMR (ppm): 55.56, 55.59, 55.64, 55.67, 64.68, 90.23, 110.27, 111.65, 111.72, 112.31, 113.16, 115.66, 120.73, 121.46, 127.67, 127.82, 128.43, 128.79, 132.45, 133.89, 148.75, 148.69, 150.38, 151.42, 156.18, 156.51, 162.85, 166.12, 168.46. EI-MS m/z (%): 568.0 (M+) (16.36 %), 153.90 (100%). Anal. Calcd (%) for C31H28N4O7 (568.58): C, 65.48; H, 4.96; N, 9.85. Found: C, 65.56; H, 4.98; N, 9.97.
N'-[2-(3-cyano-4,6-bis(3,4-dimethoxyphenyl)pyridin-2-yloxy)acetyl]-4-methoxybenzo hydrazide (9b). Yield: 69%, m.p.: 170–172 °C. IR (ν, cm−1): 3440, 3173 (NH), 2218 (CN), 1667 (C=O), 1604 (C=N), 1261, 1023 (C-O-C). 1H-NMR (ppm): 3.81 (s, 3H, OCH3), 3.84 (s, 3H, OCH3), 3.85 (s, 3H, OCH3), 3.86 (s, 3H, OCH3), 3.88 (s, 3H, OCH3),5.16 (s, 2H, OCH2), 7.01 (d, J = 9.0 Hz, 1H, dimethoxyphenyl C5-H), 7.08 (d, J = 8.4 Hz, 1H, dimethoxyphenyl C5-H), 7.17 (d, J = 8.7 , 2.1 Hz, 2H, methoxyphenyl C3,5-H), 7.32–7.35 (m 2H, dimethoxyphenyl C2,6-H), 7.81–7.90 (m, 5H, dimethoxyphenyl C2,6-H, pyridine C5-H and methoxyphenyl C2,6-H), 10.33 (s, 2H, 2NH). 13C-NMR (ppm): 55.59, 55.62, 55.64, 55.68, 55.77, 63.69, 90.17, 110.14, 111.63, 111.74, 112.13, 113.25, 114.23, 115.69, 120.74, 121.56, 125.81, 127.77, 128.43, 128.72, 148.63, 148.79, 150.44, 151.21, 156.43, 156.58, 163.12, 165.40, 165.90, 168.46. Anal. Calcd (%) for C32H30N4O8 (598.6): C, 64.21; H, 5.05; N, 9.36. Found: C, 64.37; H, 5.03; N, 9.44.
N'-[2-(3-cyano-4,6-bis(3,4-dimethoxyphenyl)pyridin-2-yloxy)acety]benzenesulfohydrazide (10a). Yield: 65%, m.p.: 120–122 °C. IR (ν, cm−1): 3454, 3233 (NH), 1711 (C=O), 1587 (C=N), 1330, 1165 (SO2), 1261, 1021 (C-O-C). 1H-NMR (ppm): 3.83 (s, 3H, OCH3), 3.85 (s, 3H, OCH3), 3.86 (s, 3H, OCH3), 3.90 (s, 3H, OCH3), 4.96 (s, 2H, OCH2), 7.06 (d, J = 9.0 Hz, 1H, dimethoxyphenyl C5-H), 7.16 (d, J = 8.9 Hz, 1H, dimethoxyphenyl C5-H), 7.23–7.85 (m, 10H, two dimethoxyphenyl C2,6-H, pyridine C5-H and phenyl-H), 10.06 (s, 1H, NH), 10.49 (s, 1H, NH). 13C-NMR (ppm): 55.48, 55.56, 55.62, 55.68, 64.66, 90.29, 110.25, 111.66, 111.74, 112.36, 113.14, 115.60, 120.69, 121.50, 127.64, 128.08, 128.47, 128.89, 132.39, 138.91, 148.68, 148.73, 150.42, 151.44, 156.22, 156.54, 162.93, 166.48. Anal. Calcd (%) for C30H28N4O8S (604.63): C, 59.59; H, 4.67; N, 9.27. Found: C, 59.78; H, 4.60; N, 9.39.
N'-[2-(3-cyano-4,6-bis(3,4-dimethoxyphenyl)pyridin-2-yloxy)acetyl]-4-methoxybenzenesulfohydrazide (10b). Yield: 65 %, m.p.: 190–192 °C. IR (ν, cm−1): 3446, 3238 (NH), 1708 (C=O), 1588 (C=N), 1333, 1166 (SO2), 1258, 1030 (C-O-C). 1H-NMR (ppm): 3.80 (s, 3H, OCH3), 3.82 (s, 3H, OCH3), 3.86 (s, 3H, OCH3), 3.87 (s, 3H, OCH3), 3.89 (s, 3H, OCH3), 4.97 (s, 2H, OCH2), 7.0 (d, J = 9.0 Hz, 1H, dimethoxyphenyl C5-H), 7.09 (d, J = 8.6 Hz, 1H, dimethoxyphenyl C5-H), 7.16 (d, J = 8.8 , 2.1 Hz, 2H, methoxyphenyl C3,5-H), 7.30–7.34 (m, 2H, dimethoxyphenyl C2,6-H), 7.82–7.88 (m, 5H, dimethoxyphenyl C2,6-H, pyridine C5-H and methoxyphenyl C2,6-H), 10.10 (s, 1H, NH), 10.48 (s, 1H, NH). 13C-NMR (ppm): 55.47, 55.58, 55.62, 55.65, 55.7), 63.6), 90.2), 110.1), 111.58, 111.76, 112.16, 113.22, 114.27, 115.73, 120.77, 121.63, 127.77, 128.43, 128.72, 130.21, 148.68, 148.81, 150.39, 151.26, 156.38, 156.62, 163.14, 165.44, 166.76. Anal. Calcd (%) for C31H30N4O9S (634.66): C, 58.67; H, 4.76; N, 8.83. Found: C, 58.78; H, 4.60; N, 9.19.

3.2.8. General Procedure for the Synthesis of Compounds 11 and 12

A mixture of 6 (0.464 g, 0.001 mol) and acetylacetone or ethyl acetoacetate (0.001 mol) in absolute ethanol/glacial acetic acid mixture (2:1) (15 mL) was heated under reflux for 8 h then allowed to cool to room temperature. The separated solid product was filtered, thoroughly washed with cold ethanol, dried and recrystallized from dimethylformamide/water mixture (4:1).
4,6-Bis(3,4-dimethoxyphenyl)-2-(2-(3,5-dimethyl-1H-pyrazol-1-yl)-2-oxoethoxy)pyridine-3-carbonitrile (11). Yield: 67%, m.p.: 161–163 °C. IR (ν, cm−1): 2215 (CN), 1705 (C=O), 1591 (C=N), 1255, 1022 (C-O-C). 1H-NMR (ppm):2.19 (s, 3H, CH3), 2.38 (s, 3H, CH3), 3.74 (s, 3H, OCH3), 3.76 (s, 3H, OCH3), 3.78 (s, 3H, OCH3), 3.80 (s, 3H, OCH3), 5.15 (s, 2H, OCH2), 6.21 (s, 1H, pyrazole C4-H), 7.10 (d, J = 8.6 Hz, 1H, dimethoxyphenyl C5-H), 7.16 (d, J = 8.3 Hz, 1H, dimethoxyphenyl C5-H), 7.33-7.38 (m, 2H, dimethoxyphenyl C2,6-H), 7.73 (d, J = 2.2 Hz, 1H, dimethoxyphenyl C2-H), 7.79 (dd, J = 8.3, 2.2 Hz, 1H, dimethoxyphenyl C6-H), 7.85 (s, 1H, pyridine C5-H). 13C-NMR (ppm):11.23, 12.54, 55.49, 55.64, 55.68, 55.71, 63.72, 90.28, 96.36, 110.41, 111.48, 111.73, 112.28, 113.36, 115.65, 120.76, 121.66, 127.79, 128.92, 142.89, 148.77, 148.85, 150.43, 151.33, 152.53, 156.28, 156.62, 162.89, 168.63. Anal. Calcd (%) for C29H28N4O6 (528.56): C, 65.90; H, 5.34; N, 10.60. Found: C, 66.08; H, 5.38; N, 10.81.
4,6-bis(3,4-Dimethoxyphenyl)-2-(2-(3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)-2-oxoethoxy)pyridine-3-carbonitrile (12). Yield: 65 %, m.p.: 189–190 °C. IR (ν, cm−1): 2216 (CN), 1708 (C=O), 1593 (C=N), 1261, 1023 (C-O-C). 1H-NMR (ppm): 2.49 (s, 3H, CH3), 3.67 (s, 2H, pyrazole C4-H2), 3.76 (s, 3H, OCH3), 3.78 (s, 3H, OCH3),3.81(s, 3H, OCH3), 3.83 (s, 3H, OCH3), 5.16 (s, 2H, OCH2), 7.10 (d, J = 8.7 Hz, 1H, dimethoxyphenyl C5-H), 7.17 (d, J = 8.3 Hz, 1H, dimethoxyphenyl C5-H), 7.33–7.38 (m, 2H, dimethoxyphenyl C2,6-H), 7.72 (d, J = 2.2 Hz, 1H, dimethoxyphenyl C2-H), 7.80 (dd, J = 8.3, 2.2 Hz, 1H, dimethoxyphenyl C6-H), 7.85 (s, 1H, pyridine C5-H). 13C-NMR (ppm): 14.95, 55.53, 55.65, 55.69, 55.96, 59.60, 63.68, 90.14, 110.29, 111.38, 111.77, 112.32, 113.44, 115.71, 120.77, 121.69, 127.88, 128.97, 142.98, 148.77, 148.85, 150.43, 151.33, 156.33, 156.67, 162.82, 162.88, 168.63. Anal. Calcd (%) for C28H26N4O7 (530.53): C, 63.39; H, 4.94; N, 10.56. Found: C, 63.47; H, 4.98; N, 10.73.

3.2.9. General Procedure for the Synthesis of Compounds 13a,b

A mixture of 6 (0.464 g, 0.001 mol) and methyl 2-cyano-3,3-bis(methylthio)acrylate or [bis (methylthio)methylene]malononitrile (0.001 mol) in dry dimethylformamide (8 mL) was heated under reflux for 5 h. The solvent was removed under vacuum and the residue was treated with ice cold water. The formed precipitate was filtered, washed with ethanol, dried and crystallized from dioxane.
Methyl 5-amino-1-{[(3-cyano-4,6-bis(3,4-dimethoxyphenyl)pyridin-2-yl)oxy]acetyl}-3-(methylsulfanyl)-1H-pyrazole-4-carboxylate (13a). Yield: 64 %, m.p.: 184–186 °C. IR (ν cm−1): 3448, 3323 (NH2), 2221 (CN), 1739, 1675 (C=O), 1622 (C=N), 1261, 1019 (C-O-C). 1H-NMR (ppm): 2.49 (s, 3H, SCH3), 3.72 (s, 3H, OCH3), 3.80 (s, 3H, OCH3), 3.86 (s, 3H, OCH3), 3.87 (s, 3H, OCH3), 3.88 (s, 3H, OCH3), 5.85 (s, 2H, OCH2), 6.99 (d, J = 8.7 Hz, 1H, dimethoxyphenyl C5-H), 7.18 (d, J = 8.4 Hz, 1H, dimethoxyphenyl C5-H), 7.34–7.38 (m, 2H, dimethoxyphenyl C2,6-H), 7.49 (s, 2H, NH2, D2O exchangeable), 7.56 (s, 1H, dimethoxyphenyl C2-H), 7.71 (d, J = 8.4 Hz, 1H, dimethoxyphenyl C6-H), 7.84 (s, 1H, pyridine C5-H). 13C-NMR (ppm): 13.15, 51.28, 55.49, 55.64, 55.68, 55.71, 63.72, 90.28, 96.36, 110.41, 111.48, 111.73, 112.28, 113.36, 115.65, 120.76, 121.66, 127.79, 128.92, 142.89, 148.77, 148.85, 150.43, 151.33, 152.53, 156.28, 156.62, 162.89, 168.63. EI-MS m/z: 619.0 (M+) (5.14%), 64.0 (100%). Anal. Calcd (%) for C30H29N5O8S (619.64): C, 58.15; H, 4.72; N, 11.30. Found: C, 58.32; H, 4.48; N, 11.13.
2-{2-[5-Amino-4-cyano-3-(methylsulfanyl)-1H-pyrazol-1-yl]-2-oxoethoxy}-4,6-bis(3,4-dimethoxyphenyl)-pyridine-3-carbonitrile (13b). Yield 59 %, m.p. 202–204 °C. IR (ν, cm−1): 3397, 3168 (NH), 2215 (CN), 1670 (C=O), 1618 (C=N), 1267, 1020 (C-O-C). 1H-NMR (ppm): 2.49 (s, 3H, SCH3), 3.80 (s, 3H, OCH3), 3.86 (s, 3H, OCH3), 3.87 (s, 3H, OCH3), 3.89 (s, 3H, OCH3), 5.11 (s, 2H, OCH2), 6.96 (d, J = 8.7 Hz, 1H, dimethoxyphenyl C5-H), 7.14–7.20 (m, 3H, dimethoxyphenyl C5-H and NH2), 7.28–7.36 (m, 2H, dimethoxyphenyl C2,6-H), 7.70 (s, 1H, dimethoxyphenyl C2-H), 7.75 (s, 1H, pyridine C5-H), 7.83 (d, J = 8.4 Hz, 1H, dimethoxyphenyl C6-H). 13C-NMR (ppm):13.26, 55.52, 55.59, 55.64, 55.76, 63.78, 90.26, 91.44, 110.41, 111.55, 111.78, 112.36, 113.39, 113.56, 115.68, 120.84, 121.73, 128.11, 128.96, 143.77, 148.78, 148.89, 150.44, 151.36, 153.59, 156.34, 156.65, 162.84, 168.63. EI-MS m/z (%): 619.0 (M+) (5.14%), 64.0 (100%). Anal. Calcd (%) for C29H26N6O6S (586.62): C, 59.38; H, 4.47; N, 14.33. Found: C, 59.69; H, 4.51; N, 14.68.
2-((5-Mercapto-1,3,4-oxadiazol-2-yl)methoxy)-4,6-bis(3,4-dimethoxyphenyl)pyridine-3-carbonitrile (14). A mixture of 6 (0.464 g, 0.001 mol), carbon disulfide (0.076 g, 0.001 mol) and potassium hydroxide (0.056 g, 0.001 mol) in ethanol (20 mL) was heated under reflux for 8 h. The reaction mixture was left to cool then poured onto crushed ice and acidified with 4N hydrochloric acid. The separated solid was filtered, washed with water, dried and crystalized from dioxane. Yield: 62%, m.p. 180–182 °C. IR (ν, cm−1): 3219 (NH), 2218 (CN), 1629 (C=N), 1262,1022(C-O-C). 1H-NMR (ppm): 3.80 (s, 3H, OCH3), 3.81 (s, 3H, OCH3), 3.82 (s, 3H, OCH3), 3.86 (s, 3H, OCH3), 5.69 (s, 2H, OCH2), 7.03 (d, J = 8.9 Hz, 1H, dimethoxyphenyl C5-H), 7.12 (d, J = 8.6 Hz, 1H, dimethoxyphenyl C5-H), 7.29–7.80 (m, 4H, two dimethoxyphenyl C2,6-H), 7.82 (s, 1H, pyridine C5-H), 12.53 (s, 1H, NH). 13C-NMR (ppm): 55.64, 55.69, 55.73, 55.76, 63.88, 90.33, 110.43, 111.54, 111.80, 112.41, 113.42, 115.70, 120.87, 121.75, 128.13, 129.11, 148.81, 148.84, 150.39, 151.45, 158.35, 156.29, 156.71, 162.88,178.30.EI-MS m/z: 507.0 (M+ /11.40%), 149 (100%). Anal. Calcd (%) for C25H22N4O6S (506.53): C, 59.28; H, 4.38; N, 11.06. Found: 59.39; H, 4.35; N, 11.22.

3.3. Biological Evaluation Methodology

3.3.1. Cell Lines and Cell Culture

The following cell lines were used for the screening stage, obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA); SK-OV-3 (HTB-77), MCF-12A (ATCC CRL-10782), MDA-MB-231 (ATCC HTB-26), HCT-116 (CCL-247), RKO (CRL-2577) and sub-culturing of the above cell lines was conducted in 75 cm2 flasks. The old culture media was removed and discarded after assessing the confluency of the cells and the cells were rinsed with 2–3 mL diluted trypsin (1×) (trypsin/EDTA solution consists of 0.025% trypsin and 0.01% EDTA in PBS), for about 5 minutes for complete detachment. The cells were observed under the inverted microscope until the cell layer is completely dispersed. 75 cm2 flasks were prepared and 16 mL of DMEM media for SK-OV-3, MCF-7, MDA-MB-231, (DMEM 4500 mg glucose) and RPMI media for HCT-116 were added to each flask. The cells were aspirated gently and added to the flasks. DMEM 4500 mg/L high glucose with 10% FBS, 5% streptomycin and penicillin, RPMI 1640 (prepared by adding 5% heat-inactivated FCS and 2 mm glutamine) were used. DMEM was also used for MCF-12A cells with the addition of human epidermal growth factor 20 ng/mL, insulin 0.01 mg/mL and hydrocortisone 500 ng/mL.

3.3.2. Drug Stock Preparation

The synthesized compounds were screened for their anti-proliferative activity using 5-FU (F6627-1G, Sigma-Aldrich, St. Louis, MO, USA) as reference compound. A concentration of 0.4% DMSO was used in all experiment after ensuring 100% viability of the cell lines with this concentration. A 25 mM stock concentration of all compounds was prepared for further studies and analysis.

3.3.3. Cell Viability Assay (WST-1 Assay)

Cells were trypsinized and placed in a 15 mL Falcon tube, the cells were centrifuged for 3 min at 1000 rpm. Trypsin is decanted using a sterile pipette and then the pellet is loosened by flicking the tube few times then 5–10 mL warm DMEM or RPMI were added to the Falcon tube and the pellet is resuspended. Cell count was done next by taking 10 μL of the suspension into the cell counting slide and read under 10× cells/mL. A cell stock of 50,000 cells/mL was prepared for the 96 wells. Cells (100 μL) were added to each well using a sterile pipette each time to ensure consistency. The experiment was planned ahead of time using excel sheet, 3–6 wells were reserved as blank media while 3–6 wells for vehicle (DMSO). The plate was incubated for 24 h for compound treatment step. DMEM media was used to prepare different dilutions of the compounds. The old DMEM media was removed from the wells using sterile pipette in the hood and the media was replaced with 100 μL media with each compound. The plate was incubated for 24 h. After 24 h incubation, WST-1 reagent (Sigma) was added to each well and then the plate was incubated for 1 h before measuring the absorbance using VICTOR™ Multilabel Plate Reader (Perkin Elmer, Beaconsfield, UK). The absorbance of the colored solution can be quantified by measuring at a certain wavelength (usually between 500–600 nm), in this experiment the first reading was conducted at 540 nm and the second reading at 690 nm for the reference wavelength. The percentage of cell viability was determined as the ratio of the absorbance of the sample vs the control. Three independent experiments were performed. The IC50 of each derivative was calculated as the concentration showing 50% cell growth inhibition during 24 h of compound treatment. 5-Florouracil (Sigma-Aldrich, F6627-1G) was used as reference standard.

3.3.4. Morphological Examination

Morphological examination was performed as described previously; MCF-7 cells were plated on 96 well plates using 5 × 104 cells/well and allowed to reach 75%–85% confluence. The compounds were added to the medium, untreated cells were used as negative control, in addition to blank cells (medium) and vehicle which consist of (DMSO 0.4% + cells). After treatment, all the cells were incubated for 24 h in an atmosphere containing 5% CO2. After 2 h of treatment, the morphological changes of the cells were examined and photographs were taken using an inverted microscope at 400× magnification.

3.3.5. TUNEL Assay

For in situ detection of apoptotic cells, a terminal-deoxynucleotidyl transferase meditated nick end labeling (TUNEL) assay was performed using DeadEndTM fluorimetric tunnel system (Promega, Madison, WI, USA). Cells were cultured on 4-chamber slides (VWR, Radnor, PA, USA) at a density of 2 × 104 cells/ chamber. After treatment with compound 9a, cells were washed with phosphate buffer saline (PBS) and fixed by incubation in 4% paraformaldehyde (PFA) for 20 min at 4 °C, then permeabilized with 0.05% Triton X-100 for 5 min at 4 °C. The fixed cells were then incubated with digoxigenin-conjugated dUTP in terminal deoxynucleotide transferase recombinant (rTdT)-catalyzed reaction and nucleotide mixture for 60 min at 37 °C in a humidified atmosphere and then immersed in stop/wash buffer for 15 min at room temperature. Cells were then washed with PBS to remove unincorporated fluorescein-12-dUTP. After washing with PBS, cells were incubated in 1 μg/mL 2-(4-amidinophenyl)-6-indole carbamidine dihydrochloride (DAPI) and fluorescein isothiocyanate (FITC) solution for 15 min in dark. Cells were observed with fluorescence microscopy (RT slider Spot, Diagnostic Instruments, Inc., Sterling Heights, MI, USA) and photographed at 100× magnification.

3.3.6. Enzyme Linked Immunosorbent Apoptosis Assay

Cells were seeded at a density of 2 × 104/ well in a 96- well plate and incubated for 24 h. Media were changed to media containing compound 9a (2 μM). Cells were then incubated for 24 h. An ELISA assay was performed using Cell Death Detection ELISA PLUS kit (Roche-Applied Science, Indianapolis, IN, USA) for the quantitative in vitro determination of cytoplasmic histone-associated DNA fragments (mono- and oligonucleosomes) in apoptosing cells. Briefly, cells were lysed with 200-μL lysis buffer for 30 min at room temperature. The lysate was centrifuged at 200 g for 10 min. 150 μL of supernatant was collected, of which 20 μL was incubated with anti-histone biotin and anti-DNA peroxidase at room temperature for 2 h. After washing with incubation buffer three times, 100 μL of substrate solution (2,2′-azino-di(3-ethylbenzthiazolinsulphonic acid) was added to each well and incubated for 15–20 min at room temperature. The absorbance was measured using an ELISA reader (Spectra Max Plus) at 405 nm. The control group was cells without compounds treatment. Each assay was done in triplicate and the standard deviation was determined.

3.3.7. Flow Cytometry

Cell Cycle Analysis

MCF-7 cells were seeded in 25 cm2 flasks until reaching the desirable confluence of 1 million cells and media was changed to media containing compound 9a (2 μM). After 24 h incubation, the cells were harvested by trypsinization to detach the cells without affecting the integrity of the cell membrane. The cells were incubated with PI for 5 min at room temperature, washed twice with PBS and fixed with ice-cold 70% ethanol while vortexing. The cells were then washed and re-suspended in PBS with 5 g/mL RNase A (Sigma) and 50 g/mL PI (Sigma) for analysis by flow cytometry. Cell cycle analysis was performed using FACScan Flow Cytometer (Becton Dickson, Franklin Lakes, NJ, USA) according to the manufacturer’s protocol.

3.3.8. Western Blot

Total protein was extracted from treated and untreated cells using lysis buffer (10 mM Tris-HCl (pH 7.5), 1 mM EDTA, 1% Triton X-100, 150 mM NaCl, 1 mM dithiothretol, 10% glycerol, 0.2 mM phenylmethysulphonyl fluoride and protease inhibitors) for 30–50 min on ice. The extracts were centrifuged at 13,000× g for 15 min at 4 °C to remove cell debris. Folin Lowry (Pierce, Grand Island, NY, USA) protein assay was used to figure the protein concentration in the cell lysates. Proteins were resolved by electrophoresis on 8%–10% sodium dodecyl sulphate-polycrylamide gel loading equal amount of proteins per lane. The resolved proteins were transferred onto polyvinylidene difluoride (PVDF) membrane and then probed with primary antibody against the protein of interest prepared in 5% milk/PBS-T. The membrane was washed using phosphate buffer saline with Tween 20 (PBS-T) and then appropriate secondary antibody conjugated to horseradish peroxidase (HRP) was used for visualization of the bands using ECL chemiluminescence kit (GE, Fairfield, CT, USA). Anti-p27, anti-CDK2, anti-CDK4, anti-(p21), anti-(p53), anti-Bax, anti-Akt, anti-Bcl-2, anti-MDM2, anti-cytochrome C, anti-caspase-8, anti-procaspase-8, anti-FAS, anti-VEGF, anti-MMP-9, anti-β-catenin were purchased from SantaCruz (Dallas, TX, USA). Pixel density of the proteins studied was calculated using Image J, version 1.41o, NIH (Bethesda, MD, USA). The values obtained were first normalized to loading control β-actin and the fold change was measured by normalizing to that of the control (0 h) value. At least two independent experiments were performed.

3.3.9. Statistical Analysis

The quantitative ratios of different groups were compared using Student’s t-test. Probability values of p < 0.05 were regarded as statistically significant. All statistical tests were two sided.

4. Conclusions

In the present study, new 3-cyano-4,6-bis (3,4-dimethoxyphenyl)-2-substituted pyridines were synthesized and investigated for their cytotoxicity on five cancer cell lines. The results demonstrated that the benzohydrazide derivative 9a reduced viability and induced apoptosis in MCF 7 breast cancer cells at an IC50 value of 2 μM and was less cytotoxic to normal breast epithelial cells (MCF-12a) than MCF 7 cells. The results of apoptosis assays and cell cycle analysis demonstrated that compound 9a obviously inhibits the proliferation of MCF-7 cancer cells by inducing apoptosis and arresting the cell cycle at G1 phase via inhibition of CDK2 and CDK4. In addition, 9a modified apoptotic response and increased the expression levels of p53, p21, p27, Bax and caspase-3, while it reduced expression levels of Bcl-2, Mdm-2 and Akt. Additionally, 9a induced the release of cytochrome c from mitochondria to cytoplasm while it has no significant effect on death-receptor related proteins FAS, procaspase-8 and caspase-8. Collectively, these results suggest that intrinsic (mitochondria) dependent pathways contributed to 9a-provoked apoptotic death in MCF-7 cells. Moreover, the expression of β-catenin and phospho AKT was downregulated by 9a. Additionally, compound 9a was found to significantly inhibit the expression of MMP-9 and VEGF. Finally, the observed data suggest that the 3-cyano-2-substituted alkoxypyridine moiety might be a potential scaffold for further development of more potent anticancer agents and compound 9a might be a promising novel therapeutic agent with anti-metastatic activities in breast cancer.

Acknowledgments

We would like to express our gratitude to Khaled Machaca, Associate Dean of Research at Weil Cornell Medical College, for supporting part of this research in his lab and for all his valuable advices.

Author Contributions

Ahmed Malki designed all molecular and cell based experiments, performed all western blot experiments, flow cytomtery and migrations assays, provided reagents/materials, interpreted all data and wrote the manuscript. Mona Mohsen performed the initial screening, cell and apoptotic assays. Zaki A. Sherif analyzed data, critically reviewed and edited the manuscript. Hassan Aziz and Mohamed El-Sayed participated in data analysis. Hayam Ashour, Ola Rizk and Omaima Shaaban designed and synthesized the target compounds and wrote the manuscript.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Weigelt, B.; Reis-Filho, J.S. Histological and molecular types of breast cancer: Is there a unifying taxonomy? Nat. Rev. Clin. Oncol. 2009, 6, 718–730. [Google Scholar] [CrossRef] [PubMed]
  2. Forouzanfar, M.H.; Foreman, K.J.; Delossantos, A.M.; Lozano, R.; Lopez, A.D.; Murray, C.J.L.; Naghavi, M. Breast and cervical cancer in 187 countries between 1980 and 2010: A systematic analysis. Lancet 2011, 378, 1461–1484. [Google Scholar] [CrossRef]
  3. O’Shaughnessy, J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist 2005, 10 (Suppl. S3), 20–29. [Google Scholar] [CrossRef] [PubMed]
  4. Vandooren, J.; Van den Steen, P.E.; Opdenakker, G. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): The next decade. Crit. Rev. Biochem. Mol. Biol. 2013, 48, 222–272. [Google Scholar] [CrossRef] [PubMed]
  5. Tinoco, G.; Warsch, S.; Glück, S.; Avancha, K.; Montero, A.J. Treating breast cancer in the 21st century: Emerging biological therapies. J. Cancer 2013, 4, 117–132. [Google Scholar] [CrossRef] [PubMed]
  6. Wind, N.S.; Holen, I. Multidrug resistance in breast cancer: From in vitro models to clinical studies. Int. J. Breast Cancer 2011, 2011, 1–12. [Google Scholar] [CrossRef] [PubMed]
  7. Fulda, S. Inhibitor of apoptosis (IAP) proteins as therapeutic targets for radiosensitization of human cancers. Cancer Treat. Rev. 2012, 38, 760–766. [Google Scholar] [CrossRef] [PubMed]
  8. Hengartner, M.O. The biochemistry of apoptosis. Nature 2000, 407, 770–776. [Google Scholar] [CrossRef] [PubMed]
  9. Perez-Rebolledo, A.; Ayala, J.D.; de Lima, G.M.; Marchini, N.; Bombieri, G.; Zani, C.L.; Souza-Fagundes, E.M.; Beraldo, H. Structural studies and cytotoxic activity of N(4)-phenyl-2-benzoylpyridine thiosemicarbazone Sn(IV) complexes. Eur. J. Med. Chem. 2005, 40, 467–472. [Google Scholar] [CrossRef] [PubMed]
  10. Kamal, A.; Khan, M.N.A.; Reddy, K.S.; Rohini, K. Synthesis of a new class of 2-anilino substituted nicotinyl arylsulfonylhydrazides as potential anticancer and antibacterial agents. Bioorg. Med. Chem. 2007, 15, 1004–1013. [Google Scholar] [CrossRef] [PubMed]
  11. Onnis, V.; Cocco, M.T.; Lilliu, V.; Congiu, C. Synthesis and evaluation of antitumoral activity of ester and amide derivatives of 2-arylamino-6-trifluoromethyl-3-pyridinecarboxylic acids. Bioorg. Med. Chem. 2008, 16, 2367–2378. [Google Scholar] [CrossRef] [PubMed]
  12. Abadi, A.H.; Ibrahim, T.M.; Abouzid, K.M.; Lehmann, J.; Tinsley, H.N.; Gary, B.D.; Piazza, G.A. Design, synthesis and biological evaluation of novel pyridine derivatives as anticancer agents and phosphodiesterase 3 inhibitors. Bioorg. Med. Chem. 2009, 17, 5974–5982. [Google Scholar] [CrossRef] [PubMed]
  13. El-Sayed, H.A.; Moustafa, A.H.; Haikal, A.E.-F.Z.; Abu-El-Halawa, R.; el Ashry, E.-S.H. Synthesis, antitumor and antimicrobial activities of 4-(4-chlorophenyl)-3-cyano-2-(β-O-glycosyloxy)-6-(thien-2-yl)-nicotinonitrile. Eur. J. Med. Chem. 2011, 46, 2948–2954. [Google Scholar] [CrossRef] [PubMed]
  14. Onnis, V.; Cocco, M.T.; Fadda, R.; Congiu, C. Synthesis and evaluation of anticancer activity of 2-arylamino-6-trifluoromethyl-3-(hydrazonocarbonyl)pyridines. Bioorg. Med. Chem. 2009, 17, 6158–6165. [Google Scholar] [CrossRef] [PubMed]
  15. Carbone, A.; Pennati, M.; Barraja, P.; Montalbano, A.; Parrino, B.; Spano, V.; Lopergolo, A.; Sbarra, S.; Doldi, V.; Zaffaroni, N.; et al. Synthesis and antiproliferative activity of substituted 3[2-(1H-indol-3-yl)-1,3-thiazol-4-yl]-1H-pyrrolo[3,2-b]pyridines, marine alkaloid Nortopsentin analogues. Curr. Med. Chem. 2014, 21, 1654–1666. [Google Scholar] [CrossRef] [PubMed]
  16. Carbone, A.; Pennati, M.; Parrino, B.; Lopergolo, A.; Barraja, P.; Montalbano, A.; Spanò, V.; Sbarra, S.; Doldi, V.; de Cesare, M.; et al. Novel 1H-Pyrrolo[2,3-b]pyridine Derivative Nortopsentin Analogues: Synthesis and Antitumor Activity in Peritoneal Mesothelioma Experimental Models. J. Med. Chem. 2013, 56, 7060–7072. [Google Scholar] [CrossRef] [PubMed]
  17. Carbone, A.; Parrino, B.; di Vita, G.; Attanzio, A.; Spanò, V.; Montalbano, A.; Barraja, P.; Tesoriere, L.; Antonia Livrea, M.; Diana, P.; et al. Synthesis and antiproliferative activity of thiazolyl-bis-pyrrolo[2,3-b]pyridines and indolyl-thiazolyl-pyrrolo[2,3-c]pyridines, Nortopsentin analogues. Mar. Drugs 2015, 13, 460–492. [Google Scholar] [CrossRef] [PubMed]
  18. Parrino, B.; Carbone, A.; Di Vita, G.; Ciancimino, C.; Attanzio, A.; Spanò, V.; Montalbano, A.; Barraja, P.; Tesoriere, L.; Antonia Livrea, M.; et al. 3-[4-(1H-Indol-3-yl)-1,3-thiazol-2-yl]-1H-pyrrolo[2,3-b]pyridines, Nortopsentin analogues with antiproliferative activity. Mar. Drugs 2015, 13, 1901–1924. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  19. Thapa, P.; Karki, R.; Thapa, U.; Jahng, Y.; Jung, M.-J.; Nam, J.M.; Na, Y.; Kwon, Y.; Lee, E.-S. 2-Thienyl-4-furyl-6-aryl pyridine derivatives: Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure–activity relationship study. Bioorg. Med. Chem. 2010, 18, 377–386. [Google Scholar] [CrossRef] [PubMed]
  20. Jun, K.-Y.; Kwon, H.; Park, S.-E.; Lee, E.; Karki, R.; Thapa, P.; Lee, J.-H.; Lee, E.-S.; Kwon, Y. Discovery of dihydroxylated 2,4-diphenyl-6-thiophen-2-yl pyridine as a non-intercalative DNA-binding topoisomerase II-specific catalytic inhibitor. Eur. J. Med. Chem. 2014, 80, 428–438. [Google Scholar] [CrossRef] [PubMed]
  21. Karki, R.; Song, C.; Kadayat, T.M.; Magar, T.B.T.; Bist, G.; Shrestha, A.; Na, Y.; Kwon, Y.; Lee, E.-S. Topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study of dihydroxylated 2,6-diphenyl-4-aryl pyridines. Bioorg.Med.Chem. 2015, 23, 3638–3654. [Google Scholar] [CrossRef] [PubMed]
  22. Kraker, A.J.; Hartl, B.G.; Amar, A.M.; Barvian, M.R.; Showalter, H.D.; Moore, C.W. Biochemical and cellular effects of c-Src-kinase-selective pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors. Biochem. Pharmacol. 2000, 60, 885–898. [Google Scholar] [CrossRef]
  23. Moasser, M.M.; Srethapakdi, M.; Sachar, K.S.; Kraker, A.J.; Rosen, N. Inhibition of Src-kinases by a selective tyrosine kinase inhibitor causes mitotic arrest. Cancer Res. 1999, 59, 6145–6152. [Google Scholar] [PubMed]
  24. Chand, K.; Prasad, S.; Tiwari, R.K.; Shirazi, A.N.; Kumar, S.; Parang, K.; Sharma, S.K. Synthesis and evaluation of c-Src-kinase inhibitory activity of pyridine 2-(1H)-one derivatives. Bioorg. Chem. 2014, 53, 75–82. [Google Scholar] [CrossRef] [PubMed]
  25. Tiwari, A.; Waud, W.R.; Struck, R.F. Determination of the phamacophore of penclomedine, a clinically evaluated antitumor pyridine derivative. Bioorg. Med. Chem. 2002, 10, 3593–3598. [Google Scholar] [CrossRef]
  26. Finch, R.A.; Liu, M.; Grill, S.P.; Rose, W.C.; Loomis, R.; Vasquez, K.M.; Cheng, Y.; Sartorelli, A.C. Triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone): A potent inhibitor of ribonucleotide reductase activitywith broad spectrum antitumor activity. Biochem. Pharmacol. 2000, 59, 983–991. [Google Scholar] [CrossRef]
  27. Wang, G.T.; Wang, X.; Wang, W.; Hasvold, L.A.; Sullivan, G.; Hutchins, C.W.; O’Conner, S.; Gentiles, R.; Sowin, T.; Cohen, J.; et al. Design and synthesis of O-trifluoromethylbiphenyl substituted 2-amino-nicotinonitriles as inhibitors of farnesyltransferase. Bioorg. Med. Chem. Lett. 2005, 15, 153–158. [Google Scholar] [CrossRef] [PubMed]
  28. Cocco, M.T.; Congiu, C.; Lilliu, V.; Onnis, V. Synthesis and antiproliferative activity of 2,6-dibenzylamino-3,5-dicyanopyridines on human cancer cell lines. Eur. J. Med. Chem. 2005, 40, 1365–1372. [Google Scholar] [CrossRef] [PubMed]
  29. Cocco, M.T.; Congiu, C.; Lilliu, V.; Onnis, V. Synthesis and in vitro antitumoral activity of new 3,5-dicyanopyridine derivatives. Bioorg. Med. Chem. 2007, 15, 1859–1867. [Google Scholar] [CrossRef] [PubMed]
  30. Rostom, S.A.F.; Faidallah, H.M.; Al-Saadi, M.S. A facile synthesis of some 3-cyano-1,4,6-trisubstituted-2(1H)pyridinones and their biological evaluation as anticancer agents. Med. Chem. Res. 2011, 20, 1260–1272. [Google Scholar] [CrossRef]
  31. Rostom, S.A.F.; Ashour, H.M.A.; Abd ElRazik, H.A. Synthesis and biological evaluation of some novel polysubstituted pyrimidine derivatives as potential antimicrobial and anticancer agents. Arch. Pharm. Chem. Life Sci. 2009, 342, 299–310. [Google Scholar] [CrossRef] [PubMed]
  32. Ashour, H.M.A.; Abdel Wahab, A.E. Synthesis and biological evaluation of novel pyrazoles and pyrazolo[3,4-d]pyrimidines incorporating a benzenesulfonamide moiety. Arch. Pharm. Chem. Life Sci. 2009, 342, 238–252. [Google Scholar] [CrossRef] [PubMed]
  33. Rostom, S.A.F.; Badr, M.H.; Abd ElRazik, H.A.; Ashour, H.M.A.; Abdel Wahab, A.E. Synthesis of some pyrazolines and pyrimidines derived from polymethoxy chalcones as anticancer and antimicrobial agents. Arch. Pharm. Chem. Life Sci. 2011, 344, 572–587. [Google Scholar] [CrossRef] [PubMed]
  34. Malki, A.; Elbayaa, R.Y.; Ashour, H.M.A.; Loffredo, C.A.; Youssef, A.M. Novel thiosemicarbazides induced apoptosis in human MCF-7 breast cancer cells via JNK signaling. J. Enzyme Inhib. Med. Chem. 2015, 30, 786–795. [Google Scholar] [CrossRef] [PubMed]
  35. Lin, C.-F.; Yang, J.-S.; Chang, C.-Y.; Kuo, S.-C.; Lee, M.-R.; Huang, L.-J. Synthesis and anticancer activity of benzyloxybenzaldehyde derivatives against HL-60 cells. Bioorg. Med. Chem. 2005, 13, 1537–1544. [Google Scholar] [CrossRef] [PubMed]
  36. Barboni, L.; Giarlo, G.; Ballini, R.; Fontana, G. 14β-hydroxy-10-deacetylbaccatin III as a convenient, alternative substrate for the improved synthesis of methoxylated second-generation taxanes. Bioorg. Med. Chem. Lett. 2006, 16, 5389–5391. [Google Scholar] [CrossRef] [PubMed]
  37. Zhou, Y.; Li, Y.; Wang, W.-J.; Xiang, P.; Luo, X.-M.; Yang, L.; Yang, S.-Y.; Zhao, Y.-L. Synthesis and biological evaluation of novel (E)-N′-(2,3-dihydro-1H-inden-1-ylidene) benzohydrazides as potent LSD1 inhibitors. Bioorg. Med. Chem. Lett. 2016, in press. [Google Scholar]
  38. Saini, M.; Kumar, P.; Kumar, M.; Ramasamy, K.; Mani, V.; Mishra, R.K.; Abdul Majeed, A.B.; Narasimhan, B. Synthesis, in vitro antimicrobial, anticancer evaluationand QSAR studies of N-(substituted)-4-(butan-2-ylideneamino)benzohydrazides. Arab. J. Chem. 2014, 7, 448–460. [Google Scholar] [CrossRef]
  39. Li, R.-D.; Wang, H.-L.; Li, Y.-B.; Wang, Z.-Q.; Wang, X.; Wang, Y.-T.; Ge, Z.-M.; Li, R.-T. Discovery and optimization of novel dual dithiocarbamates as potent anticancer agents. Eur. J. Med. Chem. 2015, 93, 381–391. [Google Scholar] [CrossRef] [PubMed]
  40. Duan, Y.-C.; Ma, Y.-C.; Zhang, E.; Shi, X.-J.; Wang, M.-M.; Ye, X.-W.; Liu, H.-M. Design and synthesis of novel 1,2,3-triazole-dithiocarbamate hybrids as potential anticancer agents. Eur. J. Med. Chem. 2013, 62, 11–19. [Google Scholar] [CrossRef] [PubMed]
  41. Nasr, T.; Bondock, S.; Youns, M. Anticancer activity of new coumarin substituted hydrazide-hydrazonederivatives. Eur. J. Med. Chem. 2014, 76, 539–548. [Google Scholar] [CrossRef] [PubMed]
  42. Baviskar, A.T.; Banerjee, U.C.; Gupta, M.; Singh, R.; Kumar, S.; Gupta, M.K.; Kumar, S.; Raut, S.K.; Khullar, M.; Singh, S.; et al. Synthesis of imine-pyrazolopyrimidinones and their mechanistic interventions on anti-cancer activity. Bioorg. Med. Chem. 2013, 21, 5782–5793. [Google Scholar] [CrossRef] [PubMed]
  43. Yu, X.; Shi, L.; Ke, S. Acylhydrazone derivatives as potential anticancer agents: Synthesis, bioevaluation and mechanism of action. Bioorg. Med. Chem. Lett. 2015, 25, 5772–5776. [Google Scholar] [CrossRef] [PubMed]
  44. Zheng, L.W.; Li, Y.; Ge, D.; Zhao, B.X.; Liu, Y.R.; Lv, H.S.; Ding, J.; Miao, J.Y. Synthesis of novel oxime-containing pyrazole derivatives and discovery of regulators for apoptosis and autophagy in A549 lung cancer cells. Bioorg. Med. Chem. Lett. 2010, 20, 4766–4770. [Google Scholar] [CrossRef] [PubMed]
  45. Zheng, L.-W.; Zhu, J.; Zhao, B.-X.; Huang, Y.-H.; Ding, J.; Miao, J.-Y. Synthesis, crystal structure and biological evaluation of novel 2-[(5-hydroxymethyl)-3-phenyl-1H-pyrazol-1-yl)-1-phenylethanol derivatives. Eur. J. Med. Chem. 2010, 45, 5792–5799. [Google Scholar] [CrossRef] [PubMed]
  46. Puthiyapurayil, P.; Poojary, B.; Chikkanna, C.; Buridipad, S.K. Design, synthesis and biological evaluation of a novel series of 1,3,4-oxadiazole bearing N-methyl-4-(trifluoromethyl)phenyl pyrazole moiety as cytotoxic agents. Eur. J. Med. Chem. 2012, 53, 203–210. [Google Scholar] [CrossRef] [PubMed]
  47. Shahzad, S.A.; Yar, M.; Bajda, M.; Jadoon, B.; Khan, Z.A.; Naqvi, S.A.R.; Shaikh, A.J.; Hayat, K.; Mahmmod, A.; Mahmood, N.; et al. Synthesis and biological evaluation of novel oxadiazole derivatives: A new class of thymidine phosphorylase inhibitors as potential anti-tumor agents. Bioorg. Med. Chem. 2014, 22, 1008–1015. [Google Scholar] [CrossRef] [PubMed]
  48. Desai, N.C.; Bhatt, N.; Somani, H.; Trivedi, A. Synthesis, antimicrobial and cytotoxic activities of some novel thiazole-clubbed 1,3,4-oxadiazoles. Eur. J. Med. Chem. 2013, 67, 54–59. [Google Scholar] [CrossRef] [PubMed]
  49. Al-Saadi, M.S.; Rostom, S.A.F.; Faidallah, H.M. Synthesis and biological evaluation of some 3-cyano-4-(1-methyl-1H-pyrrol-2-yl)-6-substituted-2(1H)-pyridinones and their 2-imino isosters. Alex. J. Pharm. Sci. 2005, 19, 15–21. [Google Scholar]
  50. Kornblum, N.; Berrigan, P.J.; le Noble, W.J. Solvation as a factor in alkylation of ambident anions: The importance of hydrogen bonding capacity of the solvent. J. Am. Chem. Soc. 1963, 85, 1141–1147. [Google Scholar] [CrossRef]
  51. Galic, N.; Peric, B.; Joji-Prodic, B.; Cimeriman, Z. Structural and spectroscopic characteristics of aroylhydrazones derived from nicotinic acid hydrazide. J. Mol. Struct. 2001, 559, 187–194. [Google Scholar] [CrossRef]
  52. Wyrzykiewicz, E.; Prukah, D. New isomeric N-substituted hydrazones of 2-, 3- and 4-pyridinecarboxaldehydes. J. Heterocycl. Chem. 1998, 35, 381–387. [Google Scholar] [CrossRef]
  53. Rando, D.G.; Sats, D.N.; Siqueira, L.; Malvezzi, A.; Leite, C.O.F.; Amaral, A.T.; Ferreira, F.I.; Tavares, L.C. Potential tuberculostatic agents. Topliss application on benzoic acid [(5-Nitrothiophen-2-yl)methylene]hydrazide series. Bioorg. Med. Chem. 2002, 10, 557–560. [Google Scholar] [CrossRef]
  54. Mohan, S.; Ananthan, S. A new approach for the synthesis of some novel sulphur bridged pyrazoles and their characterization. J. Chem. Pharm. Res. 2011, 3, 402–413. [Google Scholar]
  55. Shrivastava, H.Y.; Ravikumar, T.; Shanmugasundaram, N.; Babu, M.; Nair, B.U. Cytotoxicity studies of chromium (III) complexes on human dermal fibroblasts. Free Radic. Biol. Med. 2005, 38, 58–69. [Google Scholar] [CrossRef] [PubMed]
  56. Chu, I.M.; Hengst, L.; Slingerland, J.M. The Cdk inhibitor p27 in human cancer: Prognostic potential and relevance to anticancer therapy. Nat. Rev. Cancer 2008, 8, 253–267. [Google Scholar] [CrossRef] [PubMed]
  57. Haupt, S.; Berger, M.; Goldberg, Z.; Haupt, Y. Apoptosis–the p 53 network. J. Cell Sci. 2003, 116, 4077–4085. [Google Scholar] [CrossRef] [PubMed]
  58. Taguchi, T.; Kato, Y.; Baba, Y.; Nishimura, G.; Tanigaki, Y.; Horiuchi, C.; Mochimatsu, I.; Tsukuda, M. Protein levels of p21, p27, cyclin E and Bax predict sensitivity to cisplatin and paclitaxel in head and neck squamous cell carcinomas. Oncol. Rep. 2004, 11, 421–446. [Google Scholar]
  59. Riedl, S.J.; Shi, Y.G. Molecular mechanisms of caspase regulation during apoptosis. Nat. Rev. Mol. Cell Biol. 2004, 5, 897–907. [Google Scholar] [CrossRef] [PubMed]
  60. Pellecchia, M.; Reed, J.C. Inhibition of anti-apoptotic Bcl-2 family proteins by natural polyphenols new avenues for cancer chemoprevention and chemotherapy. Curr. Pharm. Des. 2004, 10, 1387–1398. [Google Scholar] [CrossRef] [PubMed]
  61. Shiojima, I.; Walsh, K. Role of Akt signaling in vascular homeostasis and angiogenesis. Circ. Res. 2002, 90, 1243–1250. [Google Scholar] [CrossRef] [PubMed]
  62. Dakeng, S.; Duangmano, S.; Jiratchariyahul, W.; U-Pratya, Y.; Bogler, O.; Patmasriwat, P. Inhibition of Wnt signaling by cucurbitacin B in breast cancer cells: Reduction of Wnt-associated proteins and reduced translocation of galectin-3 mediated β-catenin to the nucleus. J. Cell Biochem. 2012, 113, 49–60. [Google Scholar] [CrossRef] [PubMed]
  63. Morini, M.; Mottolese, M.; Ferrari, N.; Ghiorzo, F.; Buglioni, S.; Mortarini, R.; Noonan, D.M.; Natal, P.G.; Albini, A. The α3β1 integrin is associated with mammary carcinoma cell metastasis, invasion and gelatinase B (mmp-9) activity. Int. J. Cancer 2000, 87, 336–342. [Google Scholar] [CrossRef]
  • Sample Availability: Samples of the compounds 1–14 are available from the authors.
Molecules 21 00230 g001 550
Figure 1. Chemical structure of reported pyridines and cyanopyridines endowed with anticancer and apoptosis-inducing activities and the synthesized compounds (A,B).
Figure 1. Chemical structure of reported pyridines and cyanopyridines endowed with anticancer and apoptosis-inducing activities and the synthesized compounds (A,B).
Molecules 21 00230 g001
Molecules 21 00230 g007 550
Scheme 1. Synthesis of the target compounds 4, 5 and the key intermediate 6. For 4a–d: a, R = H; b, R = CH3; c, R = CH2CH3; d, R = COCH3; Reagents and conditions: (i) CNCH2COOEt/anhydrous CH3COONH4/EtOH/reflux; (ii) the appropriate alkyl halide/anhydrous K2CO3/dry acetone/reflux; (iii) BrCH2COOEt/anhydrous K2CO3/dry acetone/reflux; (iv) N2H4 98%/EtOH/reflux.
Scheme 1. Synthesis of the target compounds 4, 5 and the key intermediate 6. For 4a–d: a, R = H; b, R = CH3; c, R = CH2CH3; d, R = COCH3; Reagents and conditions: (i) CNCH2COOEt/anhydrous CH3COONH4/EtOH/reflux; (ii) the appropriate alkyl halide/anhydrous K2CO3/dry acetone/reflux; (iii) BrCH2COOEt/anhydrous K2CO3/dry acetone/reflux; (iv) N2H4 98%/EtOH/reflux.
Molecules 21 00230 g007
Molecules 21 00230 g008 550
Scheme 2. Synthesis of the target compounds 7–10. For 7: a, R1 = CH3; b, R1 = C2H5; c, R1 = 4-ethylmorpholine; d, R1 = 4-ethylpiperidine; 8 : a, R2 = 4-OCH3C6H4; b, R2 = 3,4-OCH3C6H3; c, R2 = 3,4,5-OCH3C6H2; 9,10: a, R3= C6H5; b, R3= 4-OCH3C6H4; Reagents and conditions: (i) CS2/KOH/DMF/the appropriate alkyl halide/RT; (ii) the appropriate aldehyde/EtOH/CH3COOH/reflux; (iii) benzoyl or p-methoxy-benzoyl chloride/dry pyridine/RT; (iv) benzenesulfonyl or p-methoxybenzenesulfonyl chloride/dry pyridine/RT.
Scheme 2. Synthesis of the target compounds 7–10. For 7: a, R1 = CH3; b, R1 = C2H5; c, R1 = 4-ethylmorpholine; d, R1 = 4-ethylpiperidine; 8 : a, R2 = 4-OCH3C6H4; b, R2 = 3,4-OCH3C6H3; c, R2 = 3,4,5-OCH3C6H2; 9,10: a, R3= C6H5; b, R3= 4-OCH3C6H4; Reagents and conditions: (i) CS2/KOH/DMF/the appropriate alkyl halide/RT; (ii) the appropriate aldehyde/EtOH/CH3COOH/reflux; (iii) benzoyl or p-methoxy-benzoyl chloride/dry pyridine/RT; (iv) benzenesulfonyl or p-methoxybenzenesulfonyl chloride/dry pyridine/RT.
Molecules 21 00230 g008
Molecules 21 00230 g002 550
Figure 2. E/Z geometrical isomers and cis/trans conformers of compounds 8a–c.
Figure 2. E/Z geometrical isomers and cis/trans conformers of compounds 8a–c.
Molecules 21 00230 g002
Molecules 21 00230 g009 550
Scheme 3. Synthesis of the target compounds 11–14. For 13: a, R = COOCH3; b, R = CN; Reagents and conditions: (i) CH2(COCH3)2/EtOH/gl. CH3COOH/reflux; (ii) CH3COCH2COOC2H5/EtOH/gl. CH3COOH/reflux; (iii) methyl 2-cyano 3,3-bis(methylsulfanyl)acrylate or 2-(bis(methylsulfanyl)-methylene)malononitrile/DMF/reflux; (iv) CS2/KOH/EtOH/reflux.
Scheme 3. Synthesis of the target compounds 11–14. For 13: a, R = COOCH3; b, R = CN; Reagents and conditions: (i) CH2(COCH3)2/EtOH/gl. CH3COOH/reflux; (ii) CH3COCH2COOC2H5/EtOH/gl. CH3COOH/reflux; (iii) methyl 2-cyano 3,3-bis(methylsulfanyl)acrylate or 2-(bis(methylsulfanyl)-methylene)malononitrile/DMF/reflux; (iv) CS2/KOH/EtOH/reflux.
Molecules 21 00230 g009
Molecules 21 00230 g003 550
Figure 3. Cytotoxicity of compound 9a on human breast cancer cells MCF-7 and non-tumorigenic breast epithelial cells MCF-12a. WST-1 Assay was performed on MCF-7 and MCF-12a after treatment with 2 μM of compound 9a for 24 h. Each data point was an average of results from three independent experiments performed in triplicate and presented as M ± SD. Significant differences between the control and test compounds are indicated by * (* p ˂ 0.05).
Figure 3. Cytotoxicity of compound 9a on human breast cancer cells MCF-7 and non-tumorigenic breast epithelial cells MCF-12a. WST-1 Assay was performed on MCF-7 and MCF-12a after treatment with 2 μM of compound 9a for 24 h. Each data point was an average of results from three independent experiments performed in triplicate and presented as M ± SD. Significant differences between the control and test compounds are indicated by * (* p ˂ 0.05).
Molecules 21 00230 g003
Molecules 21 00230 g004 550
Figure 4. Compound 9a-induced apoptosis in MCF-7 cells. (A) Morphological changes in MCF-7 cells were examined after treatment with 0.05, 0.1, 0.5, 2, 5 and 10 μM of compound 9a for 24 h. Compound 9a induces apoptotic death including marked apoptotic bodies and cell shrinkage in a concentration dependent manner. Untreated cells were used as a negative control. Treatment of MCF-7 cells with 0.4% DMSO did not show any cell death; (B) A TUNEL assay was used to confirm induction of apoptosis in MCF-7 cells. Cells were treated with 2 μM of 9a for 24 h. Untreated cells act as control. Lack of staining in control cells shows that the cells are actively proliferating, i.e., no apoptotic cell death and induction of apoptosis in treated cells was confirmed by the appearance of TUNEL-positive cells; (C) ELISA assay apoptotic cell detection. Effect of 9a on apoptosis induction in MCF-7 cells after treatment with different concentrations (i) and different time intervals (ii). Data are presented as mean ± SD (n = 3). Significant differences between the control and test compounds are indicated by * (* p ˂ 0.05); (D) Percent of distribution of cell cycle phases of MCF-7 breast cancer cells after treatment with 2 μM of 9a for 24 h. Each experiment was performed in triplicate. Data are presented as mean ± SD (n = 3); (E) Western blot analysis was carried out to quantify the expression levels of p27, CDK2 and CDK4 in treated and non-treated control cells. β-actin was used as a loading control.
Figure 4. Compound 9a-induced apoptosis in MCF-7 cells. (A) Morphological changes in MCF-7 cells were examined after treatment with 0.05, 0.1, 0.5, 2, 5 and 10 μM of compound 9a for 24 h. Compound 9a induces apoptotic death including marked apoptotic bodies and cell shrinkage in a concentration dependent manner. Untreated cells were used as a negative control. Treatment of MCF-7 cells with 0.4% DMSO did not show any cell death; (B) A TUNEL assay was used to confirm induction of apoptosis in MCF-7 cells. Cells were treated with 2 μM of 9a for 24 h. Untreated cells act as control. Lack of staining in control cells shows that the cells are actively proliferating, i.e., no apoptotic cell death and induction of apoptosis in treated cells was confirmed by the appearance of TUNEL-positive cells; (C) ELISA assay apoptotic cell detection. Effect of 9a on apoptosis induction in MCF-7 cells after treatment with different concentrations (i) and different time intervals (ii). Data are presented as mean ± SD (n = 3). Significant differences between the control and test compounds are indicated by * (* p ˂ 0.05); (D) Percent of distribution of cell cycle phases of MCF-7 breast cancer cells after treatment with 2 μM of 9a for 24 h. Each experiment was performed in triplicate. Data are presented as mean ± SD (n = 3); (E) Western blot analysis was carried out to quantify the expression levels of p27, CDK2 and CDK4 in treated and non-treated control cells. β-actin was used as a loading control.
Molecules 21 00230 g004
Molecules 21 00230 g005a 550Molecules 21 00230 g005b 550
Figure 5. Compound 9a-modulated apoptotic and survival signaling in MCF-7 cells. (A) Compound 9a up-regulated p53, p21 and Bax. Cells were treated with 2 μM of 9a for 24 h. The MCF-7 cell lysates were collected and the expression of p53, p21 and Bax was studied by western blot analysis using specific antibodies in treated and non-treated control cells. β-actin was used as a loading control; (B) Compound 9a down-regulates Bcl-2, MDM-2 and Akt levels in MCF-7 cells. Cells were treated with 2 μM 9a for 24 h. The cell lysates were collected and the expression of Bcl-2, MDM-2 and AKT was studied by western blot analysis using specific antibodies in treated and non-treated control cells. β-actin was used as a loading control; (C) Total proteins in cytosol and mitochondrial fraction were extracted and western blotting analysis was applied to determine the protein levels of cytochrome c in treated and non-treated cells; (D) Compound 9a up-regulates the level of caspase-3 in MCF-7 Cells. Cells were treated with 2 μM 9a for 24 h, cells were lysed and total protein was collected and subjected to western blot analysis to determine pro-caspase and caspase-3 proteins expression levels in treated and non-treated control cells. β-actin was used as a loading control; (E) The cell lysates were collected and the expression levels of FAS, procaspase-8 and caspase-8 was studied by western blotting analysis using specific antibodies, β-actin was used as loading control.
Figure 5. Compound 9a-modulated apoptotic and survival signaling in MCF-7 cells. (A) Compound 9a up-regulated p53, p21 and Bax. Cells were treated with 2 μM of 9a for 24 h. The MCF-7 cell lysates were collected and the expression of p53, p21 and Bax was studied by western blot analysis using specific antibodies in treated and non-treated control cells. β-actin was used as a loading control; (B) Compound 9a down-regulates Bcl-2, MDM-2 and Akt levels in MCF-7 cells. Cells were treated with 2 μM 9a for 24 h. The cell lysates were collected and the expression of Bcl-2, MDM-2 and AKT was studied by western blot analysis using specific antibodies in treated and non-treated control cells. β-actin was used as a loading control; (C) Total proteins in cytosol and mitochondrial fraction were extracted and western blotting analysis was applied to determine the protein levels of cytochrome c in treated and non-treated cells; (D) Compound 9a up-regulates the level of caspase-3 in MCF-7 Cells. Cells were treated with 2 μM 9a for 24 h, cells were lysed and total protein was collected and subjected to western blot analysis to determine pro-caspase and caspase-3 proteins expression levels in treated and non-treated control cells. β-actin was used as a loading control; (E) The cell lysates were collected and the expression levels of FAS, procaspase-8 and caspase-8 was studied by western blotting analysis using specific antibodies, β-actin was used as loading control.
Molecules 21 00230 g005aMolecules 21 00230 g005b
Molecules 21 00230 g006 550
Figure 6. Compound 9a downregulated metastatic-related genes. (A) Compound 9a down-regulated phosphoAkt and β catenin. Cells were treated with 0.5, 1 and 2 μM of 9a for 24 h. The cell lysates were collected and the expression of phospho Akt and β catenin was studied by western blot analysis using specific antibodies in treated and non-treated control cells. β-actin was used as a loading control; (B) Compound 9a down-regulated MMP 9 and VEGF. Cells were treated with 2 μM of 9a for 24 h. The cell lysates were collected and the expression of MMP 9 and VEGF was studied by western blot analysis using specific antibodies in treated and non-treated control cells. β-actin was used as a loading control. C: control (untreated cells).
Figure 6. Compound 9a downregulated metastatic-related genes. (A) Compound 9a down-regulated phosphoAkt and β catenin. Cells were treated with 0.5, 1 and 2 μM of 9a for 24 h. The cell lysates were collected and the expression of phospho Akt and β catenin was studied by western blot analysis using specific antibodies in treated and non-treated control cells. β-actin was used as a loading control; (B) Compound 9a down-regulated MMP 9 and VEGF. Cells were treated with 2 μM of 9a for 24 h. The cell lysates were collected and the expression of MMP 9 and VEGF was studied by western blot analysis using specific antibodies in treated and non-treated control cells. β-actin was used as a loading control. C: control (untreated cells).
Molecules 21 00230 g006
Table
Table 1. IC50 (μM) a of the synthesized 3-cyano-2-substituted pyridines against five cancer cell lines.
Table 1. IC50 (μM) a of the synthesized 3-cyano-2-substituted pyridines against five cancer cell lines.
Compound No.SK-OV-3 bMCF-7 cMDA-MB-231 dHCT-116 eRKO f
4a11.37 ± 0.729.08 ± 0.3732.10 ± 0.8420.30 ± 0.8513.21 ± 0.77
4b18.16 ± 0.9815.52 ± 0.4640.04 ± 1.3626.25 ± 1.2219.80 ± 0.37
4c22.12 ± 1.3212.28 ± 0.7744.93 ± 1.7410.06 ± 0.7618.14 ± 1.03
4d25.19 ± 0.7620.30 ± 0.9835.80 ± 0.9613.14 ± 0.8417.39 ± 0.44
510.15 ± 0.4415.42 ± 0.9425.12 ± 0.8714.88 ± 0.9822.13 ± 0.97
7a9.01 ± 0.4211.23 ± 0.2230.10 ± 0.8823.20 ± 0.9511.25 ± 0.91
7b12.33 ± 0.8818.14 ± 1.7637.87 ± 1.259.10 ± 0.9715.21 ± 1.13
7c5.12 ± 0.117.10 ± 0.4431.73 ± 0.8926.90 ± 0.9720.30 ± 0.76
7d10.10 ± 0.9814.30 ± 0.9535.53 ± 1.0311.16 ± 1.2624.98 ± 1.33
8a14.13 ± 0.9512.01 ± 0.9625.34 ± 1.2428.82 ± 0.3112.32 ± 0.02
8b10.21 ± 0.929.31 ± 0.9832.26 ± 0.8725.20 ± 0.8914.16 ± 0.91
8c12.14 ± 0.9815.27 ± 0.7420.31 ± 1.0625.87 ± 0.8316.32 ± 0.37
9a9.06 ± 0.242.04 ± 0.1322.34 ± 0.887.12 ± 0.378.22 ± 0.99
9b7.08 ± 0.1610.18 ± 0.9219.27 ± 0.8617.90 ± 0.749.95 ± 1.06
10a11.34 ± 0.0213.39 ± 0.9826.82 ± 0.3321.82 ± 0.8512.10 ± 1.26
10b9.17 ± 0.388.12 ± 0.4722.44 ± 1.7116.09 ± 1.0715.65 ± 0.86
1126.19 ± 0.95>50>5033.90 ± 0.87>50
1220.27 ± 1.72>50>5040.35 ± 1.76>50
13a>50>50>5036.30 ± 1.71>50
13b>50>50>5030.14 ± 0.76>50
1430.30 ± 1.12>50>50>50>50
5-FU32.19 ± 1.037.06 ± 0.9115.13 ± 0.9412.19 ± 1.1020.18 ± 1.16
a IC50 values are indicated as mean ± S.D of three independent experiments. b SK-OV-3: human ovarian carcinoma cell line. c MCF-7: human breast adenocarcinoma cell line. d MDA-MB-231: human breast adenocarcinoma cell line. e HCT-116: human colon carcinoma cell line. f RKO: human colon carcinoma cell line.

Share and Cite

MDPI and ACS Style

Malki, A.; Mohsen, M.; Aziz, H.; Rizk, O.; Shaban, O.; El-Sayed, M.; Sherif, Z.A.; Ashour, H. New 3-Cyano-2-Substituted Pyridines Induce Apoptosis in MCF 7 Breast Cancer Cells. Molecules 2016, 21, 230. https://doi.org/10.3390/molecules21020230

AMA Style

Malki A, Mohsen M, Aziz H, Rizk O, Shaban O, El-Sayed M, Sherif ZA, Ashour H. New 3-Cyano-2-Substituted Pyridines Induce Apoptosis in MCF 7 Breast Cancer Cells. Molecules. 2016; 21(2):230. https://doi.org/10.3390/molecules21020230

Chicago/Turabian Style

Malki, Ahmed, Mona Mohsen, Hassan Aziz, Ola Rizk, Omima Shaban, Mohamed El-Sayed, Zaki A. Sherif, and Hayam Ashour. 2016. "New 3-Cyano-2-Substituted Pyridines Induce Apoptosis in MCF 7 Breast Cancer Cells" Molecules 21, no. 2: 230. https://doi.org/10.3390/molecules21020230

Article Metrics

Back to TopTop